,PageNo,Text
0,page_0,Official Title: AN INTERNATIONAL STUDY TO CHARACTERISE THE DISEASE BEHAVIOUR OF IDIOPATHIC PULMONARY FIBROSIS AND INTERSTITIAL LUNG DISEASE DURING THE PERI -DIAGNOSTIC PERIOD NCT Number: NCT03261037 Document Date : Protocol Version 1: 26-A pril-2017
1,page_1,"FINAL PROTOCOL APPROVAL CONFIDENTIAL This clinical study is being sponsored globally by F. Hoffmann- La Roche Ltd of Basel, Switzerland. However, it may be implemented in individual countries by Roche’s local affiliates, including Genentech, Inc. in the United States. The information contained in this document, especially any unpublished data, is the property of F. Hoffmann- La Roche Ltd (or under its control) and therefore is provided to you in confidence as an Investigator, potential Investigator, or consultant, for review by you, your staff, and an applicable Ethics Committee or Institutional Review Board. It is understood that this information will not be disclosed to others without written authorization from Roche except to the extent necessary to obtain informed consent from persons to whom the drug may be administered. F. Hoffmann -La Roche Ltd Protocol MA39297, Version 1, 26 April 2017 PROTOCOL TITLE: AN INTERNATIONAL STUDY TO CHARACTERIZE THE DISEASE BEHAVIOUR OF IDIOPATHIC PULMONARY FIBROSIS AND INTERSTITIAL LUNG DISEASE DURING THE PERI -DIAGNOSTIC PERIOD PROTOCOL NUMBER: MA39297 VERSION NUMBER: 1 EUDRACT NUMBER: 2016- 005114- 22 IND NUMBER: N/A TEST PRODUCT: N/A MEDICAL MONITOR: SPONSOR: F. Hoffmann- La Roche Ltd DATE FINAL: See electronic date stamp below 26-Apr-2017 11:30:59 Title Approver's Name Company Signatory (Clinical) Date and Time (UTC)"
2,page_2,"F. Hoffmann -La Roche Ltd Protocol MA39297, Version 1, 2 6 April 2017 2 TABLE OF CONTENTS PROTOCOL ACCEPTANCE FORM .................................................................... 6 PROTOCOL SYNOPSIS ...................................................................................... 7 1 BACKGROUND .......................................................................................... 18 1.1 Background on Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease (IPF/ILD) ......................................... 18 1.2 Background on Test Product ................................................. 20 1.3 Study Rationale ..................................................................... 20 2 OBJECT IVES AND ENDPOINTS ............................................................... 22 3 STUDY DESIGN ......................................................................................... 24 3.1 Descriptio n of the Study ......................................................... 24 3.2 End of Study and Length of Study ......................................... 29 3.3 Rationale for Study Design and Patient Population ............... 29 3.3.1 Rationale for Disease Response– based Endpoints ............... 30 4 MATERIALS AND METHOD S .................................................................... 31 4.1 Patients .................................................................................. 31 4.1.1 Inclusion Criteria .................................................................... 31 4.1.2 Exclusion Criteria ................................................................... 31 4.2 Method of Treatment Assignment and Blinding ..................... 32 4.3 Study Treatment .................................................................... 32 4.4 Concomitant Therapy ............................................................ 32 4.4.1 Permitted Therapy ................................................................. 32 4.5 Study Assessments ............................................................... 32 4.5.1 Informed Consent Forms and Enrolment Log ........................ 32 4.5.2 Medical History, Concomitant Medication, and Demographic Data ................................................................. 32 4.5.3 Physical Examinations (including vital signs) ......................... 33 4.5.4 Disease -relevant Assessments ............................................. 33 4.5.5 Home -based Assessments .................................................... 34"
3,page_3,"F. Hoffmann -La Roche Ltd Protocol MA39297, Version 1, 2 6 April 2017 3 4.5.5.1 Daily Spirometry .................................................................... 34 4.5.5.2 Daily Physical Functional Capacity Assessments .................. 34 4.5.6 Laboratory and Other Biological Samples ............................. 34 4.5.7 Optional Biomarker Samples ................................................. 34 4.5.8 Patient -Reported Outcomes (PRO) ....................................... 36 4.6 Patient, Study, and Site Discontinuation ................................ 37 4.6.1 Patient Discontinuation from Study ........................................ 37 4.6.2 Study Discontinuation ............................................................ 37 4.6.3 Site Discontinuation ............................................................... 38 5 ASSESSMENT OF SAFETY ....................................................................... 38 5.1 Safety Plan ............................................................................ 38 6 STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN ....................... 38 6.1 Determination of Sample Size ............................................... 38 6.2 Summaries of Conduct of Study ............................................ 39 6.3 Summaries of Demographic and Baseline Characteristics ....................................................................... 40 6.4 Primary and Secondary Analyses .......................................... 40 6.4.1 Primary Endpoint ................................................................... 40 6.4.2 Secondary Endpoints ............................................................ 40 6.4.3 Exploratory Efficacy Endpoints .............................................. 41 6.5 Biomarker Analyses ............................................................... 42 6.6 Interim Analyses .................................................................... 42 7 DATA COLLECTION AND MANAGEMENT ............................................... 42 7.1 Data Quality Assurance ......................................................... 42 7.2 Electronic Case Report Forms ............................................... 43 7.3 Patient -Reported Outcome Data ........................................... 43 7.4 Source Data Documentation .................................................. 43 7.5 Use of Computerized Sy stems .............................................. 44 7.6 Retention of Records ............................................................. 44 8 ETHICAL CONSIDERATIO NS .................................................................... 45"
4,page_4,"F. Hoffmann -La Roche Ltd Protocol MA39297, Version 1, 2 6 April 2017 4 8.1 Compliance with Laws and Regulations ................................ 45 8.2 Informed Consent .................................................................. 45 8.3 Institutional Review Board or Ethics Committee .................... 46 8.4 Confidential ity ........................................................................ 46 9 STUDY DOCUMENTATION, MONITORING, AND ADMINISTRATION ..................................................................................... 47 9.1 Study Documentation ............................................................ 47 9.2 Protocol Deviations ................................................................ 47 9.3 Site Inspections ..................................................................... 47 9.4 Admi nistrative Structure......................................................... 47 9.5 Publication of Data and Protection of Trade Secrets ............. 48 9.6 Protocol Amendments ........................................................... 48 10 REFERENCES ........................................................................................... 49"
5,page_5,"F. Hoffmann -La Roche Ltd Protocol MA39297, Version 1, 2 6 April 2017 5 LIST OF TABLES Table 1 Objectives and Corresponding Endpoints ................................... 22 Table 2 Sample Size Scenarios ............................................................... 39 LIST OF FIGURES Figure 1 Study Schema ............................................................................. 25 Figure 2 Collaboration Platform ................................................................. 28 Figure 3 Study Digital Ecosystem ............................................................. 29 Figure 4 Daily FVC Measurements over Time .......................................... 56 LIST OF APPENDICES Appendix 1 Schedule of Activities .................................................................. 54 Appendix 2 Hand- Held Spirometry: Example of Disease Behavior in an Individual Patient ......................................................................... 56"
6,page_6,"F. Hoffmann -La Roche Ltd Protocol MA39297, Version 1, 2 6 April 2017 6 PROTOCOL ACCEPTANCE FORM TITLE: AN INTERNATIONAL STUDY TO CHARACTERIZE THE DISEASE BEHAVIOUR OF IDIOPATHIC PULMONARY FIBROSIS AND INTERSTITIAL LUNG DISEASE DURING THE PERI -DIAGNOSTIC PERIOD PROTOCOL NUMBER: MA39297 VERSION NUMBER: 1 EUDRACT NUMBER: 2016- 005114- 22 IND NUMBER: N/A TEST PRODUCT: N/A MEDICAL MONITOR: SPONSOR: F. Hoffmann- La Roche Ltd I agree to conduct the study in accordance with the current protocol. Principal Investigator’s Name (print) Principal Investigator’s Signature Date Please retain the signed original of this form for your study files. Please return a copy of the signed form {as instructed by XX [e.g., your local study monitor, the CRO] } [or] {to the contact provided below} . {Name} {Address}"
7,page_7,"F. H off m a n n -L a R o c h e Lt d Pr ot o c ol M A 3 9 2 9 7, V er si o n 1, 2 6 A pril 2 0 1 7 7 P R O T O C O L S Y N O P SI S TI T L E: A N I N T E R N A TI O N A L S T U D Y T O C H A R A C T E RI Z E T H E DI S E A S E B E H A VI O U R O F I DI O P A T HI C P U L M O N A R Y FI B R O SI S A N D I N T E R S TI TI A L L U N G DI S E A S E D U RI N G T H E P E RI -DI A G N O S TI C P E RI O D P R O T O C O L N U M B E R: M A 3 9 2 9 7 V E R SI O N N U M B E R: 1 E U D R A C T N U M B E R: 2 0 1 6 -0 0 5 1 1 4 -2 2 I N D N U M B E R: N/ A T E S T P R O D U C T: N/ A P H A S E: N/ A I N DI C A TI O N: I DI O P A T HI C P U L M O N A R Y FI B R O SI S / I N T E R S TI TI A L L U N G DI S E A S E S P O N S O R: F. H off m a n n -L a R o c h e Lt d O bj e cti v e s a n d E n d p oi nt s Th er e i s li mit e d d at a a v ail a bl e o n t h e e arl y c o ur s e of I P F a n d I L D . O ft e n cli ni ci a n s r e q uir e d et ail e d i nf or m ati o n o n di s e a s e b e h a vi or i n or d er t o e st a bli s h a w or ki n g di a g n o si s a n d t o d e ci d e o n f urt h er p ati e nt m a n a g e m e nt . T hi s st u d y will c h ar a ct eri z e t h e di s e a s e b e h a vi or of I P F a n d I L D i n t h e p eri -di a g n o sti c p eri o d. T hi s o bj e cti v e will b e a c hi e v e d b y u si n g a m ulti di m e n si o n al a p pr o a c h a s s e s si n g c h a n g e s i n p ul m o n ar y f u n cti o n, m e a s ur e d b y d ail y h a n d h el d s pir o m etr y , a s s e s si n g p h y si c al f u n cti o n al c a p a cit y, m e a s ur e d b y a c c el er o m etr y, a n d ot h er a s p e ct s of di s e a s e b e h a vi or ( s y m pt o m s a n d q u alit y of lif e) , b y u si n g v ari o u s P R O m e a s ur e s. F or t hi s st u d y, t h e p eri -di a g n o sti c p eri o d c o v er s : • t h e pr e -di a g n o sti c p eri o d (fr o m i n cl u si o n i nt o t h e st u d y t o di a g n o si s; f or a m a xi m u m of 1 2 m o nt h s). • t h e p o st -di a g n o sti c p eri o d (fr o m t h e di a g n o si s t o t h e st art of dr u g tr e at m e nt wit hi n 6 m o nt h s or a m a xi m u m of 6 m o nt h s aft er di a g n o si s if n o tr e at m e nt i s st art e d). S p e cifi c o bj e cti v e s a n d c orr e s p o n di n g e n d p oi nt s f or t h e st u d y ar e o utli n e d b el o w (T a bl e 1)."
8,page_8,
9,page_9,
10,page_10,"F. H off m a n n -L a R o c h e Lt d Pr ot o c ol M A 3 9 2 9 7, V er si o n 1, 2 6 A pril 2 0 1 7 1 0 di s c u s si o n a m o n g I L D e x p ert s i s k n o w n t o i n cr e a s e t h e a c c ur a c y of t h e di a g n o si s of I P F/I L D. All p ati e nt s will b e m a n a g e d at t h e di s cr eti o n of t h e I n v e sti g at or t a ki n g i nt o a c c o u nt l o c al cli ni c al pr a cti c e g ui d eli n e s a n d st a n d ar d s of c ar e a s w ell a s a v ail a bl e cli ni c al e vi d e n c e f or p ati e nt s wit h s u s p e ct e d I P F/I L D or di a g n o s e d wit h I P F/I L D. T h e st u d y s c h e m a i s s h o w n i n Fi g ur e 1. Fi g ur e 1 St u d y S c h e m a I L D =i nt er stiti al l u n g di s e a s e; I P F =i di o p at hi c p ul m o n ar y fi br o si s Fr o m i n cl u si o n i nt o t h e st u d y, p ati e nt s will b e f oll o w e d f or a m a xi m u m of 1 2 m o nt h s i n t h e pr e -di a g n o si s a s s e s s m e nt p eri o d. F oll o wi n g t h or o u g h a s s e s s m e nt s a n d di a g n o s e s, t hr e e gr o u p s of p a ti e nt s will b e i d e ntifi e d: • P ati e nt s di a g n o s e d wit h I P F. • P ati e nt s di a g n o s e d wit h a n I L D ot h er t h a n I P F. • P ati e nt s di a g n o s e d wit h a c o n diti o n t h at i s n ot a n I L D. F or i n di vi d u al p ati e nt s, t h e e n d of t h e st u d y will b e a s f oll o w s: • S h o ul d n o di a g n o si s b e m a d e 1 2 m o nt h s aft er i n cl u si o n i nt o t h e st u d y, t h e p ati e nt will l e a v e t h e st u d y. • P ati e nt s di a g n o s e d wit h a n o n -I L D c o n diti o n will l e a v e t h e st u d y o n t h e d at e of di a g n o si s."
11,page_11,"F. H off m a n n -L a R o c h e Lt d Pr ot o c ol M A 3 9 2 9 7, V er si o n 1, 2 6 A pril 2 0 1 7 1 1 • P ati e nt s di a g n o s e d wit h I P F or n o n -I P F I L D will r e m ai n a n d b e f oll o w e d i n t h e st u d y u p t o t h e st art of dr u g tr e at m e nt ( wit hi n si x m o nt h s) or a m a xi m u m of si x m o nt h s if n o dr u g tr e at m e nt i s pr e s cri b e d. “ S t art of dr u g tr e at m e nt” i s d efi n e d a s t h e d at e w h e n tr e at m e nt c o m m e n c e s . T hi s i n cl u d e s t h e e v e nt of a p ati e nt r e c ei vi n g I P F or I L D dr u g tr e at m e nt fr o m a p h y si ci a n ot h er t h a n t h e i n v e sti g at or. A c c or di n gl y , t h e t ot al l e n gt h of t h e st u d y i s v ari a bl e f or e a c h p ati e nt , wit h a m a xi m u m of 1 8 m o nt h s. Sit e vi sit s will b e c o n d u ct e d at a mi ni m u m at b a s eli n e, di a g n o si s, a n d e n d -of -st u d y f or e a c h i n di vi d u al p ati e nt. D uri n g e a c h st u d y p eri o d ( pr e - a n d p o st -di a g n o sti c p eri o d), e v er y p ati e nt s h o ul d h a v e at l e a st o n e sit e vi sit, s c h e d ul e d at t h e di s cr eti o n of t h e I n v e sti g at or. D uri n g t h e s e vi sit s, a n y r el e v a nt i nf or m ati o n s u c h a s tr e at m e nt s gi v e n a n d r e s ult s fr o m H R C T s, r a di o gr a p h s, D L C O , l u n g bi o p si e s et c. will b e c oll e ct e d, a s a v ail a bl e. T h e 6 M W T a n d F V C m e a s ur e m e nt s will b e a s s e s s e d o n -sit e a s p er t h e S c h e d ul e of A cti viti e s ( A p p e n di x 1). T h e st u d y will b e c o n d u ct e d u n d er t h e l e a d er s hi p of a St e eri n g C o m mitt e e. I n t h e a b s e n c e of t h e u s e of a n y t h er a p e uti c a g e nt, a n I n d e p e n d e nt R e vi e w C o m mitt e e I R C/I R F or a D at a S af et y M o nit ori n g B o ar d ( D S M B)/ D at a M o nit ori n g C o m mitt e e ( D M C) will n ot b e n e e d e d i n t hi s st u d y. P ati e nt st u d y -s p e cifi c a s s e s s m e nt s / st u d y kit U p o n st u d y e nr oll m e nt, e a c h p ati e nt will r e c ei v e a st u d y kit wit h a u ni q u e i d e ntifi er c o nt ai ni n g t h e f oll o wi n g: • H a n d -h el d s pir o m et er ( D e vi c e t o m e a s ur e d ail y F V C at h o m e). • A c c el er o m et er ( D e vi c e t o c o nti n u o u sl y m e a s ur e d ail y a cti viti e s , s u c h a s st e p s p er d a y, p h y si c al a cti vit y l e v el). • A t a bl et c o m p ut er f or t h e vi s u ali z ati o n of t h e s pir o m etr y a n d a c c el er o m etr y d at a a n d c o n d uit f or d at a tr a n s mi s si o n t o t h e c oll a b or ati o n pl atf or m; t h e t a bl et will b e pr e -c o nfi g ur e d t o o nl y all o w u s e f or t h e p ur p o s e of t h e st u d y. • A u s er m a n u al f or t h e a b o v e m e nti o n e d d e vi c e s. I n a d diti o n P R O m e a s ur e s will b e a s s e s s e d. P ati e nt s will c o m pl et e s p e cifi c q u e sti o n n air e s (t h e Ki n g’ s Bri ef I nt er stiti al L u n g Di s e a s e [ K -BI L D], m o difi e d M e di c al R e s e ar c h C o u n cil [ m M R C], E ur o Q o L Fi v e -Di m e n si o n 5- l e v el v er si o n [ E Q -5 D -5 L], a n d F ati g u e A s s e s s m e nt S c al e [ F A S] q u e sti o n n air e s), a n d vi s u al a n al o g u e s c al e s ( V A S) f or c o u g h , ur g e t o c o u g h, a n d f ati g u e at i n cl u si o n i n t h e st u d y a n d aft er w ar d s j u st pri or or d uri n g vi sit s, u p o n r e q u e st fr o m t h e I n v e sti g at or. I n v e sti g at or s a n d c oll a b or ati o n pl atf or m / di git al e c o -s y st e m I n v e sti g at or s will b e l o c at e d at t erti ar y r ef err al c e nt er s (I P F /I L D c e nt er s) a s w ell a s s m all er c o m m u nit y sit e s."
12,page_12,"F. Hoffmann -La Roche Ltd Protocol MA39297, Version 1, 2 6 April 2017 12 The study will provide a digital collaboration platform (Figure 2) allowing investigators from community centers to interact with experts from tertiary centers (pulmonologists, radiologists, pathologists etc.), thus creating a “virtual” MDT. The investigators from community center will be able to upload any results of diagnosis -relevant assessments such as radiographs, HRCT images. This virtual MDT will then be able to discuss each patient’s case. This platform is for the exclusive use of the investigators; the study sponsor will not have access to it. The use of the platform as a means of collaborat ion is not mandatory for participating sites. However, investigators will access the data from daily spirometry and accelerometry of their patients on the platform . Patient data will only be accessible by the treati ng physician (investigator) who can then decide to share them with the virtual MDT . These patient data will also be transferred in an anonymized way to the study database on a daily basis. Figure 2 Collaboration Platform ILD=interstitial lung disease; IPF=idiopathic pulmonary fibrosis ; MDT=multi -disciplinary team"
13,page_13,"F. Hoffmann -La Roche Ltd Protocol MA39297, Version 1, 2 6 April 2017 13 Figure 3 shows the overall study digital ecosystem. Figure 3 Study Digital Ecosystem Number of Patients Approximately 180 patients will be enrolled at about 50 study centers in seven countries (Canada, Russia and Europe) . It is assumed that approximately 40% of the patients will be diagnosed with IPF and the remaining 60% of patients will either be diagnosed with a non-IPF ILD (approximately 50%) or with a disease other than ILD or no diagnosis (approximately 10%, i.e. approx. 18 patients ). Thus, approximately 72 patients with IPF and 90 patients with non- IPF ILD are anticipated to have data available for the evaluation of the primary and secondary objectives of the study . Patients leaving the study prematurely will not be replaced. At least one tertiary center will be included in every participating country. Target Population Inclusion Criteria Patients must meet the following criteria for study entry: 1. Signed Informed Consent Form 2. Able to comply with the study protocol, in the investigator’s judgment – for example, the ability to use the provided spirometer and tablet and the ability to fill in the required patient reported outcomes questionnaires"
14,page_14,"F. Hoffmann -La Roche Ltd Protocol MA39297, Version 1, 2 6 April 2017 14 3. Age ≥50 years 4. Suspicion of IPF/ILD: Radiological evidence of I PF/ILD in symptomatic patients (unexplained dyspnea on exertion and/or cough) Exclusion Criteria Patients who meet any of the following criteria will be excluded from study entry: 1. Participation in any investigational study within 28 days prior to inclusion 2. History of clinically significant cardiac disease that could explain the patient’s symptomatology in the opinion of the investigator 3. Known history of any connective tissue disease, including, but not limited to, rheumatoid arthritis, scleroderma, systemic lupus erythematosus, or mixed connective tissue disease. End of Study The end of the clinical study is defined as the date at which the last data point which is required for the statistical analysis is received. Length of Study The first patient is expected to enroll in Q3 of 2017, and enrollment is anticipated to continue for approximately 12 months. The last patient will complete the clinical study in early 2020 at the latest. For each patient, the total length of the study is variable (up to 18 months) and depends on local clinical practice. Investigational Medicinal Products There is no investigational drug involved in the study . Statistical Methods Primary Analysis The main purpose of this study is hypothesis generation regar ding the impact on pulmonary function in terms of the change in FVC, as measured by daily handheld spirometry, in patients suspected to suffer from IPF. The primary endpoint of the study is the time- adjusted semi -annual FVC decline (in m L) in patients with IPF during the peri -diagnostic period. For the cohort under observation (i.e. patients diagnosed with IFP), the estimated time - adjusted FVC decline (m L) will be presented descriptively , along with the corresponding two- sided 95% confidence interval. The s tatistical analysis of the primary endpoint will be performed by calculating the mean FVC decline in the corresponding study cohort (i.e., patients diagnosed with IPF). The mean FVC declines will be calculated using the estimated FVC decline for each individual patient. The individual FVC decline will be estimated by applying a linear regression model to all data points collected during the study period. The mean FVC decline (m L) will also be provided for pre- specified time periods at 3, 6 or 12 months , together with corresponding 95% confidence intervals ."
15,page_15,
16,page_16,"F. Hoffmann -La Roche Ltd Protocol MA39297, Version 1, 2 6 April 2017 16 LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS Abbreviation Definition 6MWT 6-minute walk test ALAT Latin American Thoracic Association ATS American Thoracic Society BAL bronchoalveolar lavage BMI body mass index CI confidence interval CRO contract research organization DLCO carbon monoxide diffusing capacity DMC Data Monitoring Committee DNA deoxyribonucleic acid DSMB Data Safety Monitoring Board EC Ethics Committee eCRF electronic Case Report Form EDC electronic data capture EQ-5D-5L EuroQoL Five- Dimension questionnaire (5 -level version) ERS European Respiratory Society EU European Union FAS Fatigue Assessment Scale FVC forced vital capacity HRCT high-resolution computed tomography ICH International Council for Harmonisation ILD Interstitial lung disease IMP investigational medicinal product IND investigational New Drug (application) IPF idiopathic pulmonary fibrosis IRB Institutional Review Board IRC Independent Review Committee JRS Japanese Respiratory Society K-BILD King’s Brief Interstitial Lung Disease questionnaire LPLV last patient, last visit"
17,page_17,"F. Hoffmann -La Roche Ltd Protocol MA39297, Version 1, 2 6 April 2017 17 MDT multi- disciplinary team mMRC modified Medical Research Council questionnaire NGS next-generation sequencing PRO patient -reported outcome UIP usual interstitial pneumonia VAS visual analogue scale WES whole exome sequencing WGS whole genome sequencing"
18,page_18,"F. Hoffmann -La Roche Ltd Protocol MA39297, Version 1, 2 6 April 2017 18 1 BACKGROUND 1.1 Background on Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease ( IPF/ILD ) IPF is defined as a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause, occurring primarily in older adults, limited to the lungs, and associated with the radiologic and/or histopathologic pattern of usual interstitial pneumonia (UIP). The definition of IPF requires the exclusion of other forms of interstitial pneumonia including other idiopathic interstitial pneumonias and interstitial lung disease (ILD) associated with environmental exposure, medication, or systemic di sease (American Thoracic Society and European Respiratory Society 2002) . The classification of interstitial lung diseases (ILDs) requires multidisciplinary expertise with input from various clinical experts, including pulmonologists, thoracic radiologists, and lung patholog ists (Ryerson and Collard 2013) . Idiopathic pulmonary fibrosis is a rare disease; rec ent age- and gender -adjusted prevalence estimates range from 27.9 to 63.0 per 100,000 in the United States (US) by narrow and broad criteria for IPF definition, respectively. The prevalence ranged from 1.25 to 23.4 cases per 100,000 population in European Union (EU) (Fernández Pérez et al. 2010; Nalysnyk et al. 2012; Raghu et al. 2006). The observed variability in IPF prevalence may be explained by the differences in diagnostic criteria used, case definition, study population and study design. IPF is most prevalent in middle -aged and elderly patients, and most studies have found a higher frequency in men than in women (Nalysnyk et al. 2012) . Symptoms of IPF have usually been present for at least 6 months before the diagnosis is made. The initial clinical presentation is typically that of slowly progressive dyspnea and nonproductive cough. Digital clubbing occurs in up to 50% of patients. Lung auscultation reveals fine end inspiratory crackles, initially at the base of the lung and ultimately diffusely (Raghu et al. 2011). In advanced disease, features of right heart failure develop. Pulmonary function tests demonstrate a restrictive pattern, with a decrease in carbon monoxide diffusing capacity (DL CO), and oxygen desaturation on exertion. Chest radiographs show diffuse interstitial opacities with volume loss, and high -resolution computed tomography (HRCT) scans show a characteristic pattern of peripheral (subpleural), bibasilar, reticulonodular abnormalities associated with architectural distortion, honeycomb changes, and traction bronchiectasis (Raghu et al. 2011) . IPF is believed to result from a series of microinjuries to the alveolar epithelium, triggering release of profibrotic mediators. The characteristic pathologic finding on biopsy of lung tissue is a pattern of UIP with subepithelial fibroblastic foci throughout the lung."
19,page_19,"F. Hoffmann -La Roche Ltd Protocol MA39297, Version 1, 2 6 April 2017 19 Inflammation, although it may initially be present, is not typically a prominent histopathologic finding. Rather, an unremitting fibrotic response relocates from the alveolar space to the interstitium, with fibroblast and myofibroblast proliferation, organization into fibroblastic foci, and excessive collagen deposition and accumulation (American Thoracic Society and European Respiratory Society 2002; du Bois 2010) . Although the majority of patients have a history of cigarette smoking, the etiology of IPF remains unknown. The diagnosis of IPF carries a bleak prognosis, with progressive disability due to respiratory insufficiency (Hallstrand et al. 2005). Data from the placebo arm of several controlled clinical trials suggest that the rate of decline in forced vital capacity (FVC) in patients with IPF is approximately 150 to 200 mL/yr in patients with IPF(Demedts et al. 2005; Ley et al. 2011; Raghu et al. 2004, 2008) . Estimat ed survival, in the absence of treatment, is between three to five years after diagnosis (American Thoracic Society and European Respiratory Society 2002; Bjoraker et al. 1998; Douglas et al. 2000; Gribbin et al. 2006; Hyldgaard et al. 2014; Kim et al. 2006; Mapel et al. 1998; Olson et al. 2007) . A diminished quality of life in patients with IPF is well established, with impaired energy level and decreased level of independence in concert with respiratory symptoms (Swigris et al. 2005) . To date, two anti -fibrotic drugs have been approved for use in IPF: pirfenidone and nintedanib; both therapies have shown to significantly slow the progression of lung function decline in IPF (Raghu et al. 2015), although the disease remains incurable. In terms of current clinical practice, there is limited data available on the early course of disease in symptomatic patients with suspicion of IPF/ILD . Thus, the peri -diagnosis period (see definition section 2) including the pre- and post -diagnosis periods is critical to the assessment of disease behavior, the timely accurate diagnosis and the decision to treat. The study will not focus on asymptomatic stages of disease when discovery would rely on imaging techniques for lung cancer screening purposes or incidental finding. This study will characterize the disease behavior of IPF and ILD patient in the peri - diagnostic period, having as aim to increase the knowledge of the progressive nature of IPF/ILD already at early phases of assessment. This objective will be achieved using a multidimensional approach assessing changes in pulmonary function, measured by daily handheld spirometry as well as assessing physical functional c apacity."
20,page_20,"F. H off m a n n -L a R o c h e Lt d Pr ot o c ol M A 3 9 2 9 7, V er si o n 1, 2 6 A pril 2 0 1 7 2 0 1. 2 B a c k gr o u n d o n T e st Pr o d u ct T h er e i s n o i n v e sti g ati o n al dr u g i n v ol v e d i n t h e st u d y a s p ati e nt s will st o p t h e st u d y b ef or e r e c ei vi n g dr u g tr e at m e nt f or I P F/I L D. 1. 3 St u d y R ati o n al e T h e pr o p o s e d st u d y will e nr oll s y m pt o m ati c p ati e nt s wit h s u s pi ci o n of I P F/I L D. I n t er m s of c urr e nt cli ni c al pr a cti c e, t h er e i s li mit e d d at a a v ail a bl e o n t h e e arl y c o ur s e of di s e a s e a n d oft e n cli ni ci a n s r e q uir e d et ail e d i nf or m ati o n o n di s e a s e b e h a vi or i n or d er t o e st a bli s h a w or ki n g di a g n o si s a n d t o d e ci d e o n f urt h er p ati e nt m a n a g e m e nt. I n a n er a of eff e cti v e a nti -fi br oti c t h er a p y, e arl y d et e cti o n of di s e a s e pr o gr e s si o n s h o ul d pr o vi d e t h e o p p ort u nit y t o t ail or t h er a p y t o a n i n di vi d u al’ s di s e a s e ( R u s s ell et al. 2 0 1 6) . T h er ef or e, a st u d y t o c h ar a ct eri z e t h e di s e a s e b e h a vi or of I P F/I L D p ati e nt s d uri n g t h e p eri -di a g n o sti c p eri o d w o ul d pr o vi d e d at a o n t h e e arl y c o ur s e of di s e a s e. B y f oll o wi n g p ati e nt s’ l u n g f u n cti o n b ef or e a n d aft er di a g n o si s u si n g h o m e s pir o m etr y , l e v el s of p h y si c al a cti vit y , a s w ell a s s elf -a s s e s s m e nt d at a fr o m t h e p ati e nt ( p ati e nt r e p ort e d o ut c o m e s; P R O), t h e st u d y w o ul d pr o vi d e p ot e nti all y m or e r a pi d i nf or m ati o n o n di s e a s e b e h a vi or a n d e v e nt u all y pr o gr e s si o n c o m p ar e d t o u s u al cli ni c m e a s ur e m e nt s t h at o c c ur o nl y e v er y 3 -6 m o nt h s. T h e m ai n g o al s of t hi s st u d y ar e t o a s s e s s: • t h e di s e a s e b e h a vi or i n e arl y I P F/I L D p ati e nt s d uri n g t h e p eri -di a g n o sti c p eri o d • t h e f e a si bilit y of h a n d h el d s pir o m etr y i n a m ulti -c e nt er st u d y a n d it s p ot e nti al u s e i n d ail y cli ni c al pr a cti c e S e v er al s m all, g e n er all y si n gl e c e nt er cli ni c al tri al s h a v e a s s e s s e d t h e utilit y of h a n d h el d s pir o m etr y a n d p h y si c al f u n cti o n al c a p a cit y e v al u ati o n s i n p ati e nt s wit h I P F. I n di vi d u al s wit h a di a g n o si s of I P F w er e r e cr uit e d a s a s u b gr o u p of t h e Pr o s p e cti v e O b s er v ati o n of Fi br o si s i n t h e L u n g Cli ni c al E n d p oi nt s ( P R O FI L E) st u d y ( J e n ki n s et al. 2 0 1 5) . O n e of t h e o bj e cti v e s of t h e st u d y w a s t o d et er mi n e t h e f e a si bilit y a n d r eli a bilit y of m e a s uri n g d ail y F V C i n i n di vi d u al s wit h I P F ( S e e A p p e n di x 2 – E x a m pl e of Di s e a s e B e h a vi or i n a n I n di vi d u al P ati e nt u si n g h o m e s pir o m etr y ) ( R u s s ell et al. 2 0 1 6). D ail y m e a s ur e m e nt s w er e r e c or d e d b y 5 0 p ati e nt s wit h I P F u si n g h a n d h el d s pir o m et er s ( C ar e F u si o n, U nit e d Ki n g d o m) f or a m e di a n p eri o d of 2 7 9 d a y s. A n e x c ell e nt c orr el ati o n w a s o b s er v e d b et w e e n h a n d h el d s pir o m etr y a n d h o s pit al -o bt ai n e d r e a di n g s. M or e o v er, t h e r at e of d e cli n e i n F V C f oll o wi n g t h e u s e of h a n d h el d s pir o m et er s w a s hi g hl y pr e di cti v e of o ut c o m e a n d s u b s e q u e nt m ort alit y w h e n m e a s ur e d at 3, 6, a n d 1 2 m o nt h s. T h e c o n cl u si o n of t h e st u d y w a s t h at d ail y h o m e s pir o m etr y m e a s ur e m e nt s i n p ati e nt s wit h I P F ar e cli ni c all y hi g hl y i nf or m ati v e a n d, f or t h e m aj orit y of p ati e nt s, q uit e f e a si bl e t o"
21,page_21,"F. H off m a n n -L a R o c h e Lt d Pr ot o c ol M A 3 9 2 9 7, V er si o n 1, 2 6 A pril 2 0 1 7 2 1 p erf or m. H o w e v er, t h e s e o b s er v ati o n s m erit t o b e r e p e at e d a cr o s s m ulti pl e c e nt er s a n d c o u ntri e s t o e n s ur e g e n er ali z a bilit y. Wit hi n r e s pir at or y m e di ci n e, h o m e di s e a s e m o nit ori n g i n t h e f or m of p e a k fl o w m e a s ur e m e nt i s alr e a d y a f e at ur e of a st h m a s elf -m a n a g e m e nt a n d i n l u n g tr a n s pl a nt - r e ci pi e nt s. P ot e nti al cli ni c al a d v a nt a g e s of r o uti n e h o m e m o nit ori n g i n I P F i n cl u d e e arl y d et e cti o n of r a pi dl y d e cli ni n g F V C a n d m o nit ori n g of r e s p o n s e t o t h er a pi e s. H o m e m o nit ori n g c o ul d b e u s e d t o d eli v er p er s o n ali z e d p ati e nt c ar e e n a bli n g e ar l y i d e ntifi c ati o n a n d tr e at m e nt of I P F r el at e d c o m pli c ati o n s ( R u s s ell et al. 2 0 1 6) . T hi s st u d y will f oll o w p ati e nt s wit h s u s p e ct e d I P F/I L D al s o wit h r e s p e ct t o t h eir l e v el of p h y si c al a cti vit y. A G er m a n st u d y i n v e sti g at e d t h e l e v el s of p h y si c al a cti vit y i n p ati e nt s wit h I P F a n d t h e p ot e nti al a s s o ci ati o n s b et w e e n p h y si c al a cti vit y a n d l u n g f u n cti o n, e x er ci s e c a p a cit y, s y m pt o m s, a n d q u alit y -of -lif e ( B a h m er et al. 2 0 1 6) . F ort y -ei g ht p ati e nt s wit h I P F w er e i n cl u d e d a n d p h y si c al a cti vit y ( st e p s p er d a y, p h y si c al a cti vit y l e v el, a n d mi n ut e s of m o d er at e a cti vit y) w a s m e a s ur e d b y a c c el er o m etr y ( S e n s e W e ar br a c el et) f or 1 w e e k. T h e st u d y s h o w e d t h at f ati g u e a n d e x er ci s e c a p a cit y w er e str o n g a n d i n d e p e n d e nt pr e di ct or s of p h y si c al a cti vit y i n p ati e nt s wit h I P F. H o w e v er, t hi s st u d y w a s s h ort a n d di d n ot f o c u s o n p ul m o n ar y f u n cti o n a s s e s s m e nt s. A s s e s s m e nt s t h at a n al y z e t h e c o ur s e of I P F ( di s e a s e b e h a vi or) ar e li k el y t o b e c o m e a n i m p o rt a nt a s p e ct of d e ci si o n m a ki n g i n a n u p c o mi n g c o n s e n s u s p a p er fr o m t h e E ur o p e a n R e s pir at or y S o ci et y ( E R S). St u d y M A 3 9 2 9 7 will c o ntri b ut e t o t h e i m pr o v e m e nt i n t h e r a pi d a s s e s s m e nt of di s e a s e b e h a vi or. T hi s st u d y will i n v e sti g at e c o ur s e of t h e di s e a s e i n p ati e nt s wit h s u s p e ct e d I P F/I L D. B y r e c ei vi n g d at a fr o m d ail y h o m e s pir o m etr y m e a s ur e m e nt s, tr e ati n g p h y si ci a n s m a y h a v e a n i m pr o v e d c h a n c e of d et e cti n g a n e arl y d e cli n e i n l u n g f u n cti o n w hi c h m a y gi v e s u p p orti v e i nf or m ati o n i n di a g n o sti c dil e m m a’ s or g ui d e tr e at m e nt d e ci si o n s. T hi s st u d y al s o i nt e n d s t o f o st er b ett er c oll a b or ati o n s b et w e e n I P F t erti ar y r ef err al c e nt er s (I P F/I L D c e nt er s) a n d c o m m u nit y c e nt er p ul m o n ol o gi st s b y cr e ati n g a f u n cti o n al “ virt u al” m ulti -di s ci pli n ar y t e a m ( M D T) w hi c h c a n w or k t o g et h er f or t h e b e n efit of t hi s p ati e nt p o p ul ati o n. I n s u m m ar y, t h e k e y b e n efit s of t h e st u d y will i n cl u d e: • Pr o vi d i n g d at a o n t h e e arl y c o ur s e of di s e a s e a s oft e n cli ni ci a n s r e q uir e f urt h er i nf or m ati o n o n di s e a s e b e h a vi or i n or d er t o e st a bli s h a w or ki n g di a g n o si s a n d t o d e ci d e o n f urt h er p ati e nt m a n a g e m e nt."
22,page_22,
23,page_23,
24,page_24,"F. Hoffmann -La Roche Ltd Protocol MA39297, Version 1, 2 6 April 2017 24 treatment in patients with IPF ● Evaluation of the collaboration platform ● Evaluation of the usefulness, practicality , and scalability of the collaboration platform (“virtual MDT”) in normal clinic al practice by means of a survey among investigators at the end of the study ● Evaluation of the digital solution set up for the patients ● Evaluation of the usefulness and practicality of the digital solution provided to the patients by means of a patient questionnaire (daily spirometry, accelerometry) 6MWT=6 -minute walk test; FVC=forced vital capacity; ILD=interstitial lung disease; IPF=idiopathic pulmonary fibrosis; MDT= multi -disciplinary team; PRO=patient -reported outcome a) Defined by Collard and colleagues (Collard et al. 2016) 3 STUDY DESIGN 3.1 Description of the Study This is an international clinical study, without investigational medicinal product, that will enroll patients with a suspected diagnosis of IPF/ILD. The principal aim of the study is to characterize the disease behavior of IPF and ILD in the peri -diagnostic period, primarily based on changes in pulmonary function (according to changes in FVC measured by daily handheld spirometry performed at home and by site spirometry) and changes in physical functional capacity (measured by daily accelerometry performed at home and 6-minute walk tests [6MWT] measured on site). A patient will be eligible for inclusion if the Investigator has a suspicion that the patient may have IPF/ILD based on symptoms and radiological evidence. Investigators will discuss the benefits and risks of the study with the patient. The patient will subsequently be invited to participate in the study and to provide informed consent. The study conduct will be facilitated by a digital ecosystem consisting of the devices used for the home -based assessments and the digital collaboration platform used to enable a “virtual” MDT. Patients with suspected IPF/ILD should be carefully evaluated for identifiable causes of ILD. A multidisciplinary discussion among ILD experts is known to increase the accuracy of the diagnosis of IPF/ILD. All patients will be managed at the discretion of the Investigator taking into account local clinical practice guidelines and standards of care as well as available clinical evidence for patients with suspected IPF/ILD or diagnosed with IPF/ILD. The study schema is shown in Figure 1."
25,page_25,"F. H off m a n n -L a R o c h e Lt d Pr ot o c ol M A 3 9 2 9 7, V er si o n 1, 2 6 A pril 2 0 1 7 2 5 Fi g ur e 1 St u d y S c h e m a I L D =i nt er stiti al l u n g di s e a s e; I P F =i di o p at hi c p ul m o n ar y fi br o si s Fr o m i n cl u si o n i nt o t h e st u d y, p ati e nt s will b e f oll o w e d f or a m a xi m u m of 1 2 m o nt h s i n t h e pr e -di a g n o si s a s s e s s m e nt p eri o d. F oll o wi n g t h or o u g h a s s e s s m e nt s a n d di a g n o s e s, t hr e e gr o u p s of p ati e nt s will b e i d e n tifi e d: • P ati e nt s di a g n o s e d wit h I P F. • P ati e nt s di a g n o s e d wit h a n I L D ot h er t h a n I P F. • P ati e nt s di a g n o s e d wit h a c o n diti o n t h at i s n ot a n I L D. P ati e nt m a n a g e m e nt will b e i n a c c or d a n c e wit h l o c al cli ni c al pr a cti c e a n d c urr e ntl y a v ail a bl e g ui d eli n e s. F or i n di vi d u al p ati e nt s, t h e e n d of t h e st u d y will b e a s f oll o w s: • S h o ul d n o di a g n o si s b e m a d e 1 2 m o nt h s aft er i n cl u si o n i nt o t h e st u d y, t h e p ati e nt will l e a v e t h e st u d y. • P ati e nt s di a g n o s e d wit h a n o n -I L D c o n diti o n will l e a v e t h e st u d y o n t h e d at e of di a g n o si s."
26,page_26,"F. H off m a n n -L a R o c h e Lt d Pr ot o c ol M A 3 9 2 9 7, V er si o n 1, 2 6 A pril 2 0 1 7 2 6 • P ati e nt s di a g n o s e d wit h I P F or n o n -I P F I L D will r e m ai n a n d b e f oll o w e d i n t h e st u d y u p t o t h e st art of dr u g tr e at m e nt ( wit hi n si x m o nt h s) or a m a xi m u m of si x m o nt h s if n o dr u g tr e at m e nt i s pr e s cri b e d. “ St art of dr u g tr e at m e nt” i s d efi n e d a s t h e d at e t h e tr e at m e nt c o m m e n c e s . T hi s i n cl u d e s t h e e v e nt of a p ati e nt r e c ei vi n g I P F or I L D dr u g tr e at m e nt fr o m a p h y si ci a n ot h er t h a n t h e i n v e sti g at or. T h e p ati e nt will b e i n str u ct e d t o r e p ort s u c h a tr e at m e nt i m m e di at el y t o t h e i n v e sti g at or. A c c or di n gl y t h e t ot al l e n gt h of t h e st u d y i s v ari a bl e f or e a c h p ati e nt , wit h a m a xi m u m of 1 8 m o nt h s. Sit e vi sit s will b e c o n d u ct e d at a mi ni m u m at b a s eli n e, di a g n o si s, a n d e n d -of -st u d y f or e a c h i n di vi d u al p ati e nt. D uri n g e a c h st u d y p eri o d ( pr e - a n d p o st -di a g n o sti c p eri o d), e v er y p ati e nt s h o ul d h a v e at l e a st o n e sit e vi sit, s c h e d ul e d at t h e di s cr eti o n of t h e I n v e sti g at or. D uri n g t h e s e vi sit s, a n y r el e v a nt i nf or m ati o n s u c h a s tr e at m e nt s gi v e n a n d r e s ult s fr o m H R C T s, r a di o gr a p h s, D L C O , l u n g bi o p si e s et c. will b e c oll e ct e d, a s a v ail a bl e. Th e 6 M W T a n d F V C m e a s ur e m e nt s will b e a s s e s s e d o n -sit e a s p er t h e S c h e d ul e of A cti viti e s ( A p p e n di x 1). T h e st u d y will b e c o n d u ct e d u n d er t h e l e a d er s hi p of a St e eri n g C o m mitt e e ( s e e 9. 4 ). I n t h e a b s e n c e of t h e u s e of a n y t h er a p e uti c a g e nt, a n I n d e p e n d e nt R e vi e w C o m mitt e e (I R C/I R F) or a D at a S af et y M o nit ori n g B o ar d ( D S M B)/ D at a M o nit ori n g C o m mitt e e ( D M C) will n ot b e n e e d e d i n t hi s st u d y. P ati e nt st u d y -s p e cifi c a s s e s s m e nt s / st u d y kit U p o n st u d y e nr oll m e nt, e a c h p ati e nt will r e c ei v e a st u d y kit wit h a u ni q u e i d e ntifi er c o nt ai ni n g t h e f oll o wi n g: • H a n d -h el d s pir o m et er o D e vi c e t o m e a s ur e d ail y F V C at h o m e. • A c c el er o m et er o D e vi c e t o c o nti n u o u sl y m e a s ur e d ail y a cti viti e s s u c h a s st e p s p er d a y, p h y si c al a cti vit y l e v el. • A t a bl et c o m p ut er f or t h e vi s u ali z ati o n of t h e s pir o m etr y a n d a c c el er o m etr y d at a a n d c o n d uit f or d at a tr a n s mi s si o n t o t h e c oll a b or ati o n pl atf or m; t h e t a bl et will b e pr e -c o nfi g ur e d t o o nl y all o w u s e f or t h e p ur p o s e of t h e st u d y."
27,page_27,"F. H off m a n n -L a R o c h e Lt d Pr ot o c ol M A 3 9 2 9 7, V er si o n 1, 2 6 A pril 2 0 1 7 2 7 • A u s er m a n u al f or t h e a b o v e m e nti o n e d d e vi c e s. At t h e e nr oll m e nt vi sit, p ati e nt s will r e c ei v e tr ai ni n g o n t h e pr o p er u s e of t h e d e vi c e s fr o m t h e st u d y kit a n d t h e h o m e b a s e d a s s e s s m e nt s a n d will b e pr o vi d e d wit h a st e p -b y -st e p m a n u al h el pi n g t h e m c o m pl et e t h e s pir o m etr y a s s e s s m e nt s s u c c e s sf ull y. Vi s u ali zi n g t h eir d at a o n t h eir t a bl et s i s t h o u g ht t o all o w t h e m t o e v al u at e t h eir c o n diti o n a n d al s o t o i m pr o v e p ati e nt a d h er e n c e t o t h e st u d y. I n a d diti o n P R O m e a s ur e s will b e a s s e s s e d. P ati e nt s will c o m pl et e s p e cifi c q u e sti o n n air e s (t h e Ki n g’ s Bri ef I nt er stiti al L u n g Di s e a s e [ K -BI L D], m o difi e d M e di c al R e s e ar c h C o u n cil [ m M R C], E ur o Q o L Fi v e -Di m e n si o n 5- l e v el v er si o n [ E Q -5 D -5 L], a n d F ati g u e A s s e s s m e nt S c al e [ F A S] q u e sti o n n air e s), a n d vi s u al a n al o g u e s c al e s ( V A S) f or co u g h , ur g e t o c o u g h, a n d f ati g u e at t h e i n cl u si o n i n t h e st u d y a n d aft er w ar d s j u st pri or or at a s c h e d ul e d sit e vi sit, u p o n r e q u e st fr o m t h e I n v e sti g at or. I n v e sti g at or s a n d c oll a b or ati o n pl atf or m / di git al e c o -s y st e m I n v e sti g at or s will b e l o c at e d at t erti ar y r ef err al c e nt er s (I P F/I L D c e nt er s) a s w ell a s s m all er c o m m u nit y c e nt er s. T h e st u d y will pr o vi d e a di git al c oll a b or ati o n pl atf or m all o wi n g i n v e sti g at or s fr o m c o m m u nit y c e nt er s t o i nt er a ct wit h e x p ert s fr o m t erti ar y c e nt er s ( p ul m o n ol o gi st s, r a di ol o gi st s, p at h ol o gi st s et c.), t h u s cr e ati n g a “ virt u al” M D T. T h e i n v e sti g at or s fr o m c o m m u nit y c e nt er s will b e a bl e t o u pl o a d a n y r e s ult s of di a g n o si s -r el e v a nt a s s e s s m e nt s s u c h a s r a di o gr a p h s, H R C T i m a g e s. T hi s virt u al M D T will t h e n b e a bl e t o di s c u s s e a c h p ati e nt’ s c a s e. T hi s pl atf or m i s f or t h e e x cl u si v e u s e of t h e i n v e sti g at or s; t h e st u d y s p o n s or will n ot h a v e a c c e s s t o it. T h e u s e of t h e pl atf or m a s a m e a n s of c oll a b or ati o n i s n ot m a n d at or y f or p arti ci p ati n g sit e s. H o w e v er, i n v e sti g at or s will a c c e s s t h e d at a fr o m d ail y s pir o m etr y a n d a c c el er o m etr y of t h eir p ati e nt s o n t h e pl atf or m . P ati e nt d at a will o nl y b e a c c e s si bl e b y t h e tr e ati n g p h y si ci a n (i n v e sti g at or) w h o c a n t h e n d e ci d e t o s h ar e t h e m wit h t h e virt u al M D T . H o m e s pir o m etr y a n d a c c el er o m etr y d at a will al s o b e tr a n sf err e d fr o m t h e p ati e nt t a bl et t o t h e st u d y d at a b a s e i n a n a n o n y mi z e d f or m at, o n a d ail y b a si s. I n v e sti g at or tr ai ni n g will i n cl u d e tr ai ni n g o n t h e u s e of t h e c oll a b or ati o n pl atf or m. T h e c oll a b or ati o n pl atf or m (“ virt u al” M D T) t h at will b e u s e d i n t hi s st u d y i s o utli n e d i n Fi g ur e 2."
28,page_28,"F. Hoffmann -La Roche Ltd Protocol MA39297, Version 1, 2 6 April 2017 28 Figure 2 Collaboration Platform ILD=interstitial lung disease; IPF=idiopathic pulmonary fibrosis; MDT=multi -disciplinary team Figure 3 shows the overall study digital ecosystem."
29,page_29,"F. Hoffmann -La Roche Ltd Protocol MA39297, Version 1, 2 6 April 2017 29 Figure 3 Study Digital Ecosystem The ‘Study Portal for Investigators’ is a repository for study documents, including the protocol, any manuals and study updates/newsletters. It will also provide the links to the collaboration platform and the eCRF. 3.2 End of Study and Length of Study The end of the clinical study is defined as the date at which the last data point which is required for the statistical analysis is received. The first patient is expected to enroll in Q3 of 2017, and enrollment is anticipated to continue for approxi mately 12 months. The last patient will complete the clinical study in early 2020 at the latest. For each patient, the total length of the study is variable and depends on local clinical practice. 3.3 RATIONALE FOR STUDY DESIGN AND PATIENT P OPULATION This study will enroll patients with suspected IPF/ILD. In terms of current clinical practice, there is limited data available on the early course of disease and often clinicians require detailed information on disease behavior in order to establish a working diagnosis and to decide on further patient management. Therefore, a study following patients’ lung function prior to diagnosis using handheld spirometry and subsequently relating these"
30,page_30,"F. Hoffmann -La Roche Ltd Protocol MA39297, Version 1, 2 6 April 2017 30 data t o levels of activity would provide useful and early information on disease progression. This study will look into disease behavior in patients with suspected IPF/ILD. The study is meant to characterize the disease behavior of IPF and ILD and to detect potential differences in FVC decline between IPF and ILD. By receiving data from daily handheld spirometry measurements, treating physicians may have an improved chance of detecting early a decline in lung function. Improving the ability of clinicians to detect early declines could potentially lead to improvements in both diagnosis and treatment for patients with IPF/ILD. 3.3.1 Rationale for Disease Response –based Endpoints The primary objective for this study is to evaluate the change in pulmonary function (FVC measured in mL by daily handheld spirometry) from study inclusion to 6 months follow -up after a diagnosis of IPF or from study inclusion to the start of IPF drug treatment, chosen independently by the Investigator (whichever occurs sooner; see Section 2). Changes in FVC have been examined in several different clinical studies which enrolled patients with both IPF (du Bois et al. 2011a; Reichmann et al. 2015; Zappala et al. 2010) and non- IPF ILD (Solomon et al. 2013; Swigris et al. 2006; Zamora et al. 2008) and are generally accepted as a valid measure of disease course in patients with IPF/ILD. Moreover, in the single center study using handheld spirometry in 50 patients with IPF (Russell et al. 2016), the rate of decline in FVC following the use of handheld spirometers was highly predictive of outcome and subsequent mortality when measured at 3, 6, and 12 months. The conclusion of the study was that daily home spirometry measurements in patients with IPF are clinically highly informative and, for the majority of patients, quite easy to perform. Other disease response- based parameters that will be examined in this study include accelerometry, 6MWT, and various PRO measures (K -BILD, mMRC, EQ -5D-5L, FAS and c ough , urge to cough, and fatigue VAS). Some of these assessments have been used as disease response- based parameters in studies involving patients with IPF and ILD (Atkins et al. 2016; du Bois et al. 2011b; Nakayama et al. 2015; Nishiyama et al. 2010; Patel et al. 2012; Shulgina et al. 2013). The PRO measures selected are short, easy to complete, covering various aspects of the disease. Moreover, fatigue has not been assessed by PROs in major IPF trials so far, despite the fact that fatigue is common and one of most limiting symptoms for patients. Thus, assessing fatigue by FAS in this trial will generate evidence that may be relevant for patients with IPF/ILD ."
31,page_31,"F. Hoffmann -La Roche Ltd Protocol MA39297, Version 1, 2 6 April 2017 31 As diagnosis may influence health- related quality of life, the study will ensure that all PROs are repeated at the time of diagnosis and then analyzed separately for the time periods pre and post diagnosis . 4 MATERIALS AND METHOD S 4.1 Patients Approximately 180 patients will be enrolled at about 50 study centers in seven countries (Canada, Russia and Europe). It is assumed that approximately 40% of the patients will be diagnosed with IPF and the remaining 60% of patients will either be diagnosed with a non- IPF ILD (approximately 50%) or with a disease other than ILD or no diagnosis (approximately 10% , i.e. approximately 18 patients). Thus, approximately 72 patients with IPF and 90 patients with non- IPF ILD are planned to have data available for the evaluation of the primary and secondary objective s of the study. Patients leaving the study prematurely will not be replaced. At least one tertiary center will be included in every participating country. 4.1.1 Inclusion Criteria Patients must meet the follo wing criteria for study entry: 1. Signed Informed Consent Form 2. Able to comply with the study protocol, in the Investigator’s judgment – for example, the ability to use the provided spirometer and tablet and the ability to fill in the required patient reported outcomes questionnaires 3. Age ≥50 years 4. Suspicion of IPF/ILD: radiological evidence of IPF/ILD in symptomatic patients (unexplained dyspnea on exertion and/or cough). 4.1.2 Exclusion Criteria Patients who meet any of the following criteria will be excluded from study entry: 1. Participation in any inv estigational study within 28 days prior to inclusion 2. History of clinically significant cardiac disease that could explain the patient’s symptomatology in the opinion of the Investigator"
32,page_32,"F. Hoffmann -La Roche Ltd Protocol MA39297, Version 1, 2 6 April 2017 32 3. Known history of any connective tissue disease, including, but not limited to, rheumatoid arthritis, scleroderma, systemic lupus erythematosus, or mixed connective tissue disease. 4.2 Method of Treatment Assignment and Blinding No investigational drug is involved in the study and therefore no treatment blinding will occur during the study. 4.3 Study Treatment No investigational drug is involved in the study. During the study, patients will be managed according to the standard of care at the discretion of the Investigator. 4.4 Concomitant Therapy Concomitant therapy consists of any medication (e.g., prescription drugs, over -the- counter drugs, vaccines, herbal or homeopathic remedies, nutritional supplements) used by a patient from inclusion until the end of the study. All such medications should be reported to the Investigator and recorded on the Concomitant Medications eCRF. 4.4.1 Permitted Therapy All medications taken by the patient for concomitant disease(s) should be continued as necessary during the study and be recorded on the eCRF. 4.5 Study Assessmen ts The schedule of activities to be performed during the study is provided in Appendix 1. All activities must be performed and documented for each patient. 4.5.1 Informed Consent Forms and Enrol lment Log Written informed consent for participation in the study must be obtained before performing any study -related procedures. Signed Informed Consent Forms for enrolled patients will be maintained at the study site file. All evaluations must be completed and reviewed to confirm that patients meet all eligibility criteria before enrollment. The Investigator will maintain an enrollment log to record details of all patients screened and to confirm eligibility or record reasons for enrollment failure, as applicable. 4.5.2 Medical History, Concomitant Medication, and Demographi c Data Medical history, including clinically significant respiratory diseases, (asthma, chronic obstructive pulmonary disease, and pneumonia), reproductive status, smoking"
33,page_33,"F. Hoffmann -La Roche Ltd Protocol MA39297, Version 1, 2 6 April 2017 33 history, and use of alcohol and drugs of abuse, will be recorded at baseline. In addition, all medications will be recorded as described in section 4.4. Demographic data will include age, gender, and self -reported race/ethnicity (if country appropriate). 4.5.3 Physical Examinations (including vital signs) Physical examinations will be conducted as per the schedule of activities (see Appendix 1). The directed physical examination should be based on signs and symptoms of the patient. Physicians should pay particular attention to the signs and symptoms that are characteristic of IPF or ILD. Additional physical examinations may be performed only if clinically indicated. Physical examinations will include weight (kg); in addition, at baseline, the examination will include height (cm) , and body mass index (BMI) will be calculated. Physical examination is the responsibility of the principal Investigator or medically qualified designee. 4.5.4 Disease- relevant Assessments Disease -relevant data potentially collected may include, but are not limited to, pulmonary function tests (FVC and DL CO), physical functional capacity (6MWT and accelerometry data), and results from bronchoalveolar lavage (BAL), HRCTs, radiographs, and lung biopsy. FVC will be conducted on site at each patient visit. The 6MWT will be conducted at each patient visit, only at sites where a formalized process is available and the test can be performed under safe conditions . Patients will visit the site for assessment at baseline, diagnosis and end- of-study as well as at least once during each study period (pre- and post -diagnosis). During these visits HRCTs, radiographs, DL CO, and lung biopsies may also be conducted and the results will be recorded. Further information on the assessments (e.g., FVC, 6MWD, PROs) that will be conducted as part of this study can be found in the Procedure Manual."
34,page_34,"F. H off m a n n -L a R o c h e Lt d Pr ot o c ol M A 3 9 2 9 7, V er si o n 1, 2 6 A pril 2 0 1 7 3 4 4. 5. 5 H o m e -b a s e d A s s e s s m e nt s A s d e s cri b e d i n s e cti o n 3. 1 , at t h e e nr oll m e nt vi sit, p ati e nt s will r e c ei v e tr ai ni n g o n t h e u s e of t h e c o m p o n e nt s of t h e st u d y kit – t h e s pir o m et er, t h e a c c el er o m et er a n d t h e t a bl et c o m p ut er. T h e p ati e nt s will b e a bl e t o s e e t h e r e s ult s of t h eir d ail y s pir o m etr y a n d a c c el er o m et er r e a di n g s pr e s e nt e d gr a p hi c all y o n t h e t a bl et c o m p ut er. D at a fr o m t h e t a bl et will b e a ut o m ati c all y s e nt t o t h e c oll a b or ati o n pl atf or m a n d e C R F s. T h e y will al s o r e c ei v e s et s of p a p er -b a s e d P R O q u e sti o n n air e s a n d s c al e s f or c o m pl eti o n pri or t o sit e vi sit s. T h e s e q u e sti o n n air e s c a n h o w e v er al s o b e c o m pl et e d o n sit e, if t h e p ati e nt f or g et s t o, or i s ot h er wi s e u n a bl e t o c o m pl et e t h e m at h o m e b ef or e t h e vi sit. 4. 5. 5. 1 D ail y S pir o m etr y Thr o u g h o ut t h e st u d y, p ati e nt s will p erf or m a s pir o m etr y r e a di n g of F V C [ m L] at a p pr o xi m at el y t h e s a m e ti m e e a c h d a y. F or t hi s p ur p o s e, st u d y p arti ci p a nt s will b e pr o vi d e d wit h a p ort a bl e h a n d h el d s pir o m et er a n d a t a bl et c o m p ut er. E a c h s pir o m et er will b e f a ct or y c ali br at e d. 4. 5. 5. 2 D ail y P h y si c al F u n cti o n al C a p a cit y A s s e s s m e nt s P ati e nt will b e a s k e d t o w e ar a n a c c el er o m et er w hi c h pr o vi d e s i nf or m ati o n o n t h eir p h y si c al a cti vit y, s u c h a s st e p s p er d a y a n d c al ori e e x p e n dit ur e. 4. 5. 6 L a b or at or y a n d Ot h er Bi ol o gi c al S a m pl e s N o s a m pl e s will b e c oll e ct e d d uri n g t hi s st u d y f or m a n d at or y a s s e s s m e nt of l a b or at or y p ar a m et er s or m a n d at or y bi o m ar k er s. 4. 5. 7 O pti o n al Bi o m ar k er S a m pl e s T h e st u d y i s ai mi n g t o c oll e ct t w o o pti o n al b a s eli n e s a m pl e s, o nl y at sit e s w h er e a p pr o pri at e i nfr a str u ct ur e i s a v ail a bl e . T h e f oll o wi n g o pti o n al bi o m ar k er s a m pl e s will b e c oll e ct e d a s p er t h e S c h e d ul e of A s s e s s m e nt s ( s e e A p p e n di x 1) a n d s e nt t o t h e S p o n s or or a d e si g n e e f or a n al y si s: • o n e s er u m s a m pl e ( pr e p ar e d fr o m 8 m L of w h ol e bl o o d) • o n e w h ol e bl o o d s a m pl e ( 6 m L) T h e s er u m s a m pl e at b a s eli n e will b e a v ail a bl e f or a n al y si s of bi o m ar k er s t h at m a y b e i n v ol v e d i n t h e d e v el o p m e nt a n d pr o gr e s si o n of I P F/I L D."
35,page_35,"F. Hoffmann -La Roche Ltd Protocol MA39297, Version 1, 2 6 April 2017 35 Baseline protein biomarkers will also be examined to look for differences between patients with suspected IPF who later become diagnosed with IPF versus those who do not. Additionally, baseline protein biomarkers may be examined for correlations with other clinical outcomes measured such as activity and quality of life. The whole blood sample will be collected at baseline for deoxyribonucleic acid (DNA) extraction to examine genetic polymorphisms and their potential role in the pathogenesis and associated clinical outcomes of IPF. Patient participation for this assessment is voluntary , and declining participation to collect biomarker samples will not influence eligibility for this trial. Any samples remaining after analyses have been conducted will be destroyed no later than five years after the end of the study (see definition for End of Study in Section 3.2). The above whole blood sample may be sent to one or more laboratories for analysis of germline or somatic mutations via whole genome sequencing (WGS), whole exome sequencing (WES), next -generation sequencing (NGS), or other genomic anal ysis methods. Genomics is increasingly informing researcher's understanding of disease pathobiology. WGS and WES provide a comprehensive characterization of the genome"
36,page_36,"F. H off m a n n -L a R o c h e Lt d Pr ot o c ol M A 3 9 2 9 7, V er si o n 1, 2 6 A pril 2 0 1 7 3 6 a n d e x o m e, r e s p e cti v el y, a n d, al o n g wit h cli ni c al d at a c oll e ct e d i n t hi s st u d y, m a y i n c r e a s e t h e o p p ort u nit y f or d e v el o pi n g n e w t h er a p e uti c a p pr o a c h e s. D at a will b e a n al y z e d i n t h e c o nt e xt of t hi s st u d y b ut will al s o b e e x pl or e d i n a g gr e g at e wit h d at a fr o m ot h er st u di e s. T h e a v ail a bilit y of a l ar g er d at a s et will a s si st i n i d e ntifi c ati o n of i m p ort a nt p at h w a y s, g ui di n g t h e d e v el o p m e nt of n e w t ar g et e d a g e nt s. F or s a m pli n g pr o c e d ur e s, st or a g e c o n diti o n s, a n d s hi p m e nt i n str u cti o n s, s e e t h e l a b or at or y m a n u al. W h e n a p ati e nt wit h dr a w s fr o m t h e st u d y, s a m pl e s c oll e ct e d pri or t o t h e d at e of wit h dr a w al m a y still b e a n al y z e d, u nl e s s t h e p ati e nt s p e cifi c all y r e q u e st s t h at t h e s a m pl e s b e d e str o y e d or l o c al l a w s r e q uir e d e str u cti o n of t h e s a m pl e s. D at a ari si n g fr o m s a m pl e a n al y si s, i n cl u di n g g e n e pr o m ot er p ol y m or p hi s m s, will b e s u bj e ct t o t h e c o nfi d e nti alit y st a n d ar d s d e s cri b e d i n S e cti o n 8. 4 . 4. 5. 8 P ati e nt -R e p ort e d O ut c o m e s ( P R O) V ari o u s p a p er -b a s e d P R O q u e sti o n n air e s a n d vi s u al a n al o g s c al e s will b e u s e d t o m o nit or t h e p ati e nt s’ h e alt h st at u s a n d w ell -b ei n g d uri n g t h e st u d y: • Ki n g' s Bri ef I nt er stiti al L u n g Di s e a s e ( K -BI L D) Q u e sti o n n air e. T hi s q u e sti o n n air e w a s s p e cifi c all y d e v el o p e d t o a n al y z e t h e h e alt h st at u s of p ati e nt s wit h I L D ( P at el et al. 2 0 1 2). T h e q u e sti o n n air e c o n si st s of 1 5 it e m s t h at ar e c o m pil e d i nt o t hr e e d o m ai n s of br e at hl e s s n e s s a n d a cti viti e s, p s y c h ol o gi c al, a n d c h e st s y m pt o m s. • M o difi e d M e di c al R e s e ar c h C o u n cil ( m M R C) D y s p n e a S c al e. T h e m M R C c hr o ni c d y s p n e a s c al e i s si m pl e t o a d mi ni st er a n d h a s b e e n u s e d f or m a n y y e ar s t o gr a d e t h e eff e ct s of br e at hl e s s n e s s o n d ail y a cti viti e s ( P a piri s et al. 2 0 0 5) . T h e s c al e c o n si st s of si x c at e g ori e s a b o ut p er c ei v e d br e at hl e s s n e s s w hi c h r a n g e fr o m n o d y s p n e a ( C at e g or y 0) t o a v er y s e v er e d e gr e e of d y s p n e a ( C at e g or y 5). • T h e E ur o Q ol 5 -Di m e n si o n Q u e sti o n n air e ( E Q -5 D -5 L). T h e 5 -l e v el v er si o n ( E Q - 5 D -5 L) i s a v ali d at e d s elf -r e p ort h e alt h st at u s q u e sti o n n air e ( B r o o k s 1 9 9 6; E ur o Q ol Gr o u p 1 9 9 0; H er d m a n et al. 2 0 1 1; J a n s s e n et al. 2 0 1 3) . T h er e ar e t w o c o m p o n e nt s t o t h e E Q -5 D -5 L: o a fi v e -it e m h e alt h st at e pr ofil e t h at a s s e s s e s m o bilit y, s elf -c ar e, u s u al a cti viti e s, p ai n/ di s c o mf ort, a n d a n xi et y/ d e pr e s si o n o a V A S t h at m e a s ur e s h e alt h st at e."
37,page_37,"F. H off m a n n -L a R o c h e Lt d Pr ot o c ol M A 3 9 2 9 7, V er si o n 1, 2 6 A pril 2 0 1 7 3 7 • F ati g u e A s s e s s m e nt S c al e ( F A S) . T h e F A S i s a f ati g u e q u e sti o n n air e c o n si sti n g of 1 0 it e m s; fi v e q u e sti o n s r efl e ct p h y si c al f ati g u e a n d fi v e q u e sti o n s a n al y z e m e nt al f ati g u e ( D e Vri e s et al. 2 0 0 4) . A fi v e -p oi nt s c al e ( o n e f or n e v er t o fi v e f or al w a y s) i s u s e d f or p ati e nt r e s p o n s e s a n d t h er ef or e F A S s c or e s c a n r a n g e fr o m 1 0 t o 5 0. • C o u g h / Ur g e t o c o u g h / F ati g u e Vi s u al A n al o g u e S c al e s ( V A S). T h e V A S ar e 1 0 0 m m s c al e s o n w hi c h p ati e nt s i n di c at e t h e s e v erit y of t h eir c o u g h, t h e ur g e t o c o u g h a n d t h eir f ati g u e ( M ori c e et al. 2 0 0 7) . T h e a b o v e P R O q u e sti o n n air e s, tr a n sl at e d, v ali d at e d i nt o t h e l o c al l a n g u a g e, will b e c o m pl et e d i n t h eir e ntir et y b y t h e p ati e nt s at b a s eli n e at t h e st u d y sit e, a n d t h e n j u st pri or t o or d uri n g t h eir n e xt s c h e d ul e d sit e vi sit, f oll o wi n g a r e q u e s t fr o m t h e I n v e sti g at or. T o e n s ur e i n str u m e nt v ali dit y a n d t h at d at a st a n d ar d s m e et h e alt h a ut h orit y r e q uir e m e nt s, q u e sti o n n air e s will b e s elf -a d mi ni st er e d pri or t o t h e p ati e nt r e c ei vi n g a n y i nf or m ati o n o n di s e a s e st at u s a n d pri or t o t h e p erf or m a n c e of a n y n o n -P R O a s s e s s m e nt s. T h e q u e sti o n n air e s s h o ul d al w a y s b e c o m pl et e d i n t h e s a m e or d er. F urt h er i nf or m ati o n o n t h e s e P R O a s s e s s m e nt s, w hi c h will b e c o n d u ct e d a s p art of t hi s st u d y, c a n b e f o u n d i n t h e Pr o c e d ur e M a n u al. 4. 6 P ati e nt, St u d y, a n d Sit e Di s c o nti n u ati o n 4. 6. 1 P ati e nt Di s c o nti n u ati o n fr o m St u d y P ati e nt s h a v e t h e ri g ht t o v ol u nt aril y wit h dr a w fr o m t h e st u d y at a n y ti m e f or a n y r e a s o n. I n a d diti o n, t h e I n v e sti g at or h a s t h e ri g ht t o wit h dr a w a p ati e nt fr o m t h e st u d y at a n y ti m e. R e a s o n s f or wit h dr a w al fr o m t h e st u d y m a y i n cl u d e, b ut ar e n ot li mit e d t o, t h e f oll o wi n g: • P ati e nt wit h dr a w al of c o n s e nt • St u d y t er mi n ati o n or sit e cl o s ur e • P ati e nt n o n -c o m pli a n c e, d efi n e d a s f ail ur e t o c o m pl y wit h pr ot o c ol r e q uir e m e nt s a s d et er mi n e d b y t h e I n v e sti g at or or S p o n s or E v er y eff ort s h o ul d b e m a d e t o o bt ai n i nf or m ati o n o n p ati e nt s w h o wit h dr a w fr o m t h e st u d y. T h e pri m ar y r e a s o n f or wit h dr a w al fr o m t h e st u d y s h o ul d b e d o c u m e nt e d o n t h e a p pr o pri at e e C R F. If a p ati e nt r e q u e st s t o b e wit h dr a w n fr o m t h e st u d y, t hi s r e q u e st m u st b e d o c u m e nt e d i n t h e s o ur c e d o c u m e nt s a n d si g n e d b y t h e I n v e sti g at or. P ati e nt s w h o wit h dr a w fr o m t h e st u d y will n ot b e r e pl a c e d. 4. 6. 2 St u d y Di s c o nti n u ati o n T h e S p o n s or h a s t h e ri g ht t o t er mi n at e t hi s st u d y at a n y ti m e. R e a s o n s f or t er mi n ati n g t h e st u d y m a y i n cl u d e, b ut ar e n ot li mit e d t o, t h e f oll o wi n g:"
38,page_38,"F. H off m a n n -L a R o c h e Lt d Pr ot o c ol M A 3 9 2 9 7, V er si o n 1, 2 6 A pril 2 0 1 7 3 8 • P ati e nt e nr oll m e nt i s u n s ati sf a ct or y T h e S p o n s or will n otif y t h e i n v e sti g at or if t h e S p o n s or d e ci d e s t o di s c o nti n u e t h e st u d y. 4. 6. 3 Sit e Di s c o nti n u ati o n T h e S p o n s or h a s t h e ri g ht t o cl o s e a sit e at a n y ti m e. R e a s o n s f or cl o si n g a sit e m a y i n cl u d e, b ut ar e n ot li mit e d t o, t h e f oll o wi n g: • P o or pr ot o c ol a d h er e n c e • N o n -c o m pli a n c e wit h t h e I nt er n ati o n al C o u n cil f or H ar m o ni s ati o n (I C H) g ui d eli n e f or G o o d Cli ni c al Pr a cti c e • N o st u d y a cti vit y (i. e., all p ati e nt s h a v e c o m pl et e d t h e st u d y a n d all o bli g ati o n s h a v e b e e n f ulfill e d) 5 A S S E S S M E N T O F S A F E T Y 5. 1 S af et y Pl a n T hi s st u d y h a s n o pr ot o c ol m a n d at e d i n v e sti g ati o n al m e di ci n al pr o d u ct (I M P) or tr e at m e nt r e q uir e m e nt s. P ati e nt s will st o p t h e st u d y pri or t o st arti n g a n y dr u g tr e at m e nt f or I P F/I L D, a s d e s cri b e d i n s e cti o n 3. 1 . A n y o c c urr e n c e s of n o n -el e cti v e h o s pit ali z ati o n, I n v e sti g at or -r e p ort e d a c ut e e x a c er b ati o n s, d e at h s, a n d e v e nt s r el at e d t o st u d y a s s e s s m e nt s s h o ul d b e c oll e ct e d i n t h e e C R F o nl y. It will b e t h e r e s p o n si bilit y of t h e I n v e sti g at or t o m a n a g e t h e s e e v e nt s a p pr o pri at el y. A n y u nt o w ar d o c c urr e n c e s t h o u g ht t o b e d u e t o, or a s s o ci at e d wit h, a c o m m er ci al m e di ci n al pr o d u ct u s e d d uri n g t h e c o ur s e of a p ati e nt’ s st a n d ar d m e di c al tr e at m e nt will n ot b e r e p ort e d i n t h e e C R F s, b ut s h o ul d b e r e p ort e d t o t h e r e s p e cti v e M ar k et A ut h ori z ati o n H ol d er or l o c al H e alt h A ut h orit y a c c or di n g t o l o c al r e g ul at or y r e q uir e m e nt s. 6 S T A TI S TI C A L C O N SI D E R A TI O N S A N D A N A L Y SI S P L A N 6. 1 D et er mi n ati o n of S a m pl e Si z e T h e m ai n p ur p o s e of t hi s st u d y i s h y p ot h e si s g e n er ati o n a n d e sti m ati o n r e g ar di n g t h e i m p a ct o n p ul m o n ar y f u n cti o n i n t er m s of t h e c h a n g e i n F V C, a s m e a s ur e d b y d ail y h a n d h el d s pir o m etr y, i n p ati e nt s s u s p e ct e d t o s uff er fr o m I P F."
39,page_39,"F. Hoffmann -La Roche Ltd Protocol MA39297, Version 1, 2 6 April 2017 39 For this study, a total sample size of approximately 180 patients is planned (Table 2). The majority of the patients will be enrolled into two study cohorts, i.e., patients with a diagnosis of IPF or non -IPF ILD. Due to the uncertainty of the numbers of patients to be enrolled into these two cohorts, the sample size cannot be derived for a certain patient number. For the purpose of sample size and power calculation, it is assumed that approximately 40% of patients will be diagnosed with IPF and 50% of patients will be diagnosed with non- IPF ILD. Approximately 10% of patients are expected to suffer from a disease other than ILD (non -ILD) or will not have a diagnosis within 12 months of enrollment. This assumption is based on published data (Wapenaar -deKorver et al. 2016) . Thus, it is expected to enroll approx. 72 patients with a diagnosis of IPF and approx. 90 patients with a diagnosis of non- IPF ILD. Approximately 18 patients may be diagnosed with non- ILD or have no diagnosis within the 12 months period following enrollment. Table 2 Sample Size S cenarios Number of patients with IPF Mean FVC decline [mL] over 6 months Lower Bound of 95% CI Upper Bound of 95% CI Total number of patients to be enrolled 72 25 8.83 41.17 180 72 50 33.83 66.17 180 72 75 58.83 91.17 180 CI = confidence interval In Table 2 point estimates and 95% confidence intervals based on a normal distribution are tabulated for a range of possible outcomes, assuming 72 patients analyzed, a standard deviation of 70 ml, and a precision of 16.17% (estimates produced using nQuery, version 7). A mean semi -annual FVC decline in the IPF group of 50 mL is considered being a clinically relevant decline and a reasonable expectation in accordance with the literature (Ley et al. 2011). In addition, after inspect ion of historical data, it can be assumed that the common standard deviation in mean FVC decline is 70 mL as measured by handheld spirometry. 6.2 Summaries of Conduct of Study The number of patients who enroll, discontinue, or complete the study will be summarized by diagnosis cohort. Reasons for premature study withdrawal will be listed and summarized. Enrollment and major protocol deviations will be listed and evaluated for their potential effects on the interpretation of study results."
40,page_40,"F. H off m a n n -L a R o c h e Lt d Pr ot o c ol M A 3 9 2 9 7, V er si o n 1, 2 6 A pril 2 0 1 7 4 0 A c o h ort of p ati e nt s w h o c o ul d n ot b e di a g n o s e d d uri n g t h e fir st y e ar aft er i n cl u si o n i nt o t h e st u d y will b e a n al y z e d s e p ar at el y a s w ell. 6. 3 S u m m ari e s of D e m o gr a p hi c a n d B a s eli n e C h ar a ct eri sti c s D e m o gr a p hi c a n d b a s eli n e c h ar a ct eri sti c s s u c h a s a g e, s e x a n d r a c e ( w h er e p er mi s si bl e) will b e s u m m ari z e d u si n g m e a n s, st a n d ar d d e vi ati o n s, m e di a n s, a n d r a n g e s f or c o nti n u o u s v ari a bl e s a n d pr o p orti o n s f or c at e g ori c al v ari a bl e s, a s a p pr o pri at e. S u m m ari e s will b e pr e s e nt e d b y di a g n o si s c o h ort. A s u m m ar y of c o n c o mit a nt m e di c ati o n s will b e di s pl a y e d i n fr e q u e n c y t a bl e s. 6. 4 Pri m ar y a n d S e c o n d ar y A n al y s e s T h e m ai n p ur p o s e of t hi s st u d y i s h y p ot h e si s g e n er ati o n a n d e sti m ati o n r e g ar di n g t h e i m p a ct o n p ul m o n ar y f u n cti o n i n t er m s of t h e c h a n g e i n F V C, a s m e a s ur e d b y d ail y h a n d h el d s pir o m etr y, i n p ati e nt s wit h s u s p e ct e d t o s uff er fr o m I P F. 6. 4. 1 Pri m ar y E n d p oi nt T h e pri m ar y e n d p oi nt of t h e st u d y i s t h e ti m e -a dj u st e d s e mi -a n n u al F V C d e cli n e (i n m L) i n p ati e nt s wit h I P F d uri n g t h e p eri -di a g n o sti c p eri o d. F or t h e c o h ort u n d er o b s er v ati o n (i. e. p ati e nt s di a g n o s e d wit h I F P), t h e e sti m at e d ti m e - a dj u st e d F V C d e cli n e ( m L) will b e pr e s e nt e d d e s cri pti v el y, al o n g wit h t h e c orr e s p o n di n g t w o -si d e d 9 5 % c o nfi d e n c e i nt er v al. T h e st ati sti c al a n al y si s of t h e pri m ar y e n d p oi nt will b e p erf or m e d b y c al c ul ati n g t h e m e a n F V C d e cli n e i n t h e c orr e s p o n di n g st u d y c o h ort (i. e., p ati e nt s di a g n o s e d wit h I P F). T h e m e a n F V C d e cli n e s will b e c al c ul at e d u si n g t h e e sti m at e d F V C d e cli n e f or e a c h i n di vi d u al p ati e nt. T h e i n di vi d u al F V C d e cli n e will b e e sti m at e d b y a p pl yi n g a li n e ar r e gr e s si o n m o d el t o all d at a p oi nt s c oll e ct e d d uri n g t h e e ntir e st u d y p eri o d. I n a d diti o n , a si n gl e ar m r e p e at e d m e a s ur e s mi x e d m o d el will b e a p pli e d t o e sti m at e t h e F V C d e cli n e o v er 6 m o nt h s a s a s e n siti vit y a n al y si s . T h e m e a n F V C d e cli n e ( m L) will al s o b e pr o vi d e d f or pr e -s p e cifi e d ti m e p eri o d s at 3, 6 or 1 2 m o nt h s, t o g et h er wit h c orr e s p o n di n g 9 5 % c o nfi d e n c e i nt er v al s. 6. 4. 2 S e c o n d ar y E n d p oi nt s • T h e c h a n g e i n p ul m o n ar y f u n cti o n t e st s ( F V C m e a s ur e d i n m L b y d ail y h o m e s pir o m etr y ) i n p ati e nt s wit h n o n -I P F I L D will b e a n al y z e d i n t h e s a m e f a s hi o n a s t h e pri m ar y e n d p oi nt ."
41,page_41,"F. H off m a n n -L a R o c h e Lt d Pr ot o c ol M A 3 9 2 9 7, V er si o n 1, 2 6 A pril 2 0 1 7 4 1 • T h e c h a n g e i n p ul m o n ar y f u n cti o n t e st s ( m L a n d % pr e di ct e d F V C) b y sit e s pir o m etr y will b e a n al y z e d i n t h e s a m e f a s hi o n a s t h e pri m ar y e n d p oi n t. Ti m e a dj u st e d m e a n c h a n g e s a n d c orr e s p o n di n g 9 5 % c o nfi d e n c e i nt er v al s will b e pr o vi d e d f or e a c h di a g n o si s c o h ort. • T h e c h a n g e i n 6 M W T will b e a n al y z e d d e s cri pti v el y o v er ti m e f or e a c h di a g n o si s c o h ort • T h e c h a n g e i n p h y si c al f u n cti o n al c a p a cit y ( m e a s ur e d b y d ail y h o m e a c c el er o m etr y, e. g. n u m b er of f o ot st e p s p er d a y a n d c al ori e e x p e n dit ur e) will b e a n al y z e d d e s cri pti v el y o v er ti m e f or e a c h di a g n o si s c o h ort • T h e c h a n g e i n P R O m e a s ur e s will b e a n al y z e d d e s cri pti v el y o v er ti m e f or e a c h di a g n o si s c o h ort • T h e c orr el ati o n of F V C ( m L) b et w e e n h o m e a n d sit e s pir o m etr y will b e a n al y z e d b y c al c ul ati n g P e ar s o n’ s c orr el ati o n c o effi ci e nt t a ki n g t h e i n di vi d u al m e a n F V C d e cli n e s f or e a c h p ati e nt i nt o a c c o u nt • T h e c orr el ati o n b et w e e n p h y si c al f u n cti o n al c a p a cit y a s s e s s e d at h o m e i n t er m s of t h e d e cli n e i n t h e n u m b er of f o ot st e p s a n d o n sit e i n t er m s of t h e d e cli n e i n di st a n c e of t h e 6 M W T will b e a n al y z e d b y c al c ul ati n g P e ar s o n’ s c orr el ati o n c o effi ci e nt t a ki n g t h e i n di vi d u al v al u e s f or e a c h p ati e nt i nt o a c c o u nt • A c o m p ari s o n of di s e a s e b e h a vi or i n I P F a n d n o n -I P F I L D p ati e nt s will b e s u m m ari z e d d e s cri pti v el y • E v al u at e t h e b a s eli n e c h ar a ct eri sti c s of pr o gr e s si n g v s n o n -pr o gr e s si n g p ati e nt s, p ati e nt s r e q uiri n g r e s pir at or y -r el at e d h o s pit ali z ati o n s • T h e i n ci d e n c e r at e of n o n -el e cti v e h o s pit ali z ati o n, b ot h r e s pir at or y a n d all c a u s e will b e s u m m ari z e d d e s cri pti v el y b y di a g n o si s c o h ort • T h e i n ci d e n c e of I n v e sti g at or -r e p ort e d a c ut e e x a c er b ati o n s will b e s u m m ari z e d d e s cri pti v el y b y di a g n o si s c o h ort • I n ci d e n c e of d e at h, all c a u s e a n d r e s pir at o r y -r el at e d d e at h s will b e s u m m ari z e d d e s cri pti v el y b y di a g n o si s c o h ort • T h e i n ci d e n c e of e v e nt s r el at e d t o t h e st u d y a s s e s s m e nt s will b e s u m m ari z e d d e s cri pti v el y b y di a g n o si s c o h ort 6. 4. 3 E x pl or at or y Effi c a c y E n d p oi nt s • Diff er e nt I L D s u b gr o u p s, e. g. c o n n e cti v e ti s s u e di s e a s e a s s o ci at e d I L D, c hr o ni c h y p er s e n siti vit y p n e u m o niti s I L D, will b e a n al y z e d i n t er m s of b a s eli n e c h ar a ct eri sti c s a n d c h a n g e i n F V C ( ml) d uri n g t h e e ntir e st u d y p eri o d d e p e n di n g o n t h e a v ail a bl e d at a"
42,page_42,"F. H off m a n n -L a R o c h e Lt d Pr ot o c ol M A 3 9 2 9 7, V er si o n 1, 2 6 A pril 2 0 1 7 4 2 • E v al u at e t h e c h ar a ct eri sti c s ( b a s eli n e c h ar a ct eri sti c s, c h a n g e s i n p ul m o n ar y f u n cti o n a n d p h y si c al a cti vit y) of p ati e nt s wit h n o di a g n o si s m a d e 1 2 m o nt h s aft er i n cl u si o n i nt o t h e st u d y • E v al u ati o n of t h e diff er e n c e s i n F V C v al u e s at b e gi n ni n g of tr e at m e nt, d e p e n di n g o n r ei m b ur s e m e nt r e stri cti o n s • E v al u ati o n of t h e c oll a b or ati o n pl atf or m b y I n v e sti g at or s • E v al u ati o n of t h e di git al s ol uti o n s et u p f or p ati e nt s F urt h er d et ail s o n t h e a n al y s e s o n st u d y c o h ort s a n d e x pl or at or y effi c a c y e n d p oi nt s will b e pr o vi d e d i n t h e St ati sti c al A n al y si s Pl a n. 6. 5 Bi o m ar k er A n al y s e s Bi o m ar k er v ari a bl e s will b e s u m m ari z e d u si n g d e s cri pti v e st ati sti c s: m e a n s/ m e di a n s, st a n d ar d d e vi ati o n a n d r a n g e f or c o nti n u o u s v ari a bl e s a n d fr e q u e n c y t a bl e s f or c at e g ori c al v ari a bl e s. It s r el ati o n s hi p t o pri m ar y a n d s e c o n d ar y e n d p oi nt s m a y b e e x pl or e d . D et ail s o n t h e s e st ati sti c al m et h o d s will b e pr o vi d e d i n a s e p ar at e st ati sti c al a n al y si s pl a n. 6. 6 I nt eri m A n al y s e s I nt eri m a n al y s e s will b e p erf or m e d at l e a st o n c e p er y e ar. T h e fir st i nt eri m a n al y si s i s pl a n n e d w h e n 2 0 p ati e nt s e nr oll e d ar e di a g n o s e d wit h I P F a n d c a n b e f ull y e v al u at e d wit h r e g ar d t o t h e pr e -di a g n o sti c p eri o d. 7 D A T A C O L L E C TI O N A N D M A N A G E M E N T 7. 1 D at a Q u alit y A s s ur a n c e A c o ntr a ct r e s e ar c h or g a ni z ati o n ( C R O) will b e r e s p o n si bl e f or t h e d at a m a n a g e m e nt of t hi s st u d y, i n cl u di n g q u alit y c h e c ki n g of t h e d at a. D at a e nt er e d m a n u all y will b e c oll e ct e d vi a el e ctr o ni c d at a c a pt ur e ( E D C) t hr o u g h t h e u s e of e C R F s ( el e ctr o ni c c a s e r e c or d f or m s). Sit e s will b e r e s p o n si bl e f or d at a e ntr y i nt o t h e E D C s y st e m. I n t h e e v e nt of di s cr e p a nt d at a, t h e C R O will r e q u e st d at a cl arifi c ati o n fr o m t h e sit e s, w hi c h t h e sit e s will r e s ol v e el e ctr o ni c all y i n t h e E D C s y st e m. T h e S p o n s or will p erf or m o v er si g ht of t h e d at a m a n a g e m e nt of t hi s st u d y. T h e S p o n s or will pr o d u c e a n E D C St u d y S p e cifi c ati o n d o c u m e nt t h at d e s cr i b e s t h e q u alit y c h e c ki n g t o b e p erf or m e d o n t h e d at a."
43,page_43,"F. Hoffmann -La Roche Ltd Protocol MA39297, Version 1, 2 6 April 2017 43 eCRFs and correction documentation will be maintained in the EDC system’s audit trail. System backups for data stored by the Sponsor and records retention for the study data will be consistent with the Sponsor’s standard procedures. 7.2 Electronic Case Report Forms eCRFs are to be completed through use of a Sponsor -designated EDC system. Sites will receive training and have access to a manual for appropriate eCRF completion. eCRFs will be submitted electronically to the Sponsor and should be handled in accordance with instructions from the Sponsor. All eCRFs should be completed by designated, trained site staff. eCRFs should be reviewed and electronically signed and dated by the Investigator or a designee. At the end of the study, the Investigator will receive patient data for his or her site in a readable format on a compact disc that must be kept with the study records. Acknowledgement of receipt of the compact disc is required. 7.3 Patient -Reported Outcome D ata PRO data will be collected on paper questionnaires. The data from the questionnaires will be entered into the EDC system. The electronic data will be available for view access only, via a secure method. Only identified and trained users may view the data, and their actions will become part of the audit trail. The Sponsor will have view access only. System backups for data stored by the Sponsor and records retention for the study data will be consistent with the Sponsor’s standard procedures. Once the s tudy is complete, the data, audit trail, and study and system documentation will be archived. The Investigator will keep all PRO forms completed by the patient in the study records as source data. In addition, the site will receive all data in a machine-readable format on a compact disc. Acknowledgement of receipt of the compact disc is required. 7.4 Source Data Documentation Study monitors will perform ongoing source data verification and review to confirm that critical protocol data (i.e., source data) entered into the eCRFs by authorized site personnel are accurate, complete, and verifiable from source documents. Source documents (paper or electronic) are those in which patient data are recorded and documented for the first time. They include, but are not limited to, hospital records,"
44,page_44,"F. Hoffmann -La Roche Ltd Protocol MA39297, Version 1, 2 6 April 2017 44 clinical and office charts, laboratory notes, memoranda, patient -reported outcomes, evaluat ion checklists, recorded data from automated instruments, copies of transcriptions that are certified after verification as being accurate and complete, microfiche, photographic negatives, microfilm or magnetic media, X -rays, patient files, and records kept at pharmacies, laboratories, and medicotechnical departments involved in a clinical trial. Before study initiation, the types of source documents that are to be generated will be clearly defined in the Trial Monitoring Plan. This includes any protocol data to be entered directly into the eCRFs (i.e., no prior written or electronic record of the data) and considered source data. Source documents that are required to verify the validity and completeness of data entered into the eCRFs must not be obliterated or destroyed and must be retained per the policy for retention of records described in Section 7.6. To facilitate source data verification and review, the Investigators and institutions must provide the Sponsor direct access to applicable source documents and reports for trial - related monitoring, Sponsor audits, and Institutional Review Board (IRB)/Ethics Committee (EC) review. The study site must also allow inspection by applicable health authorities. 7.5 Use of Computerized Systems When clinical observations are entered directly into a study site’s computerized medical record system (i.e., in lieu of original hardcopy records), the electronic record can serve as the source document if the system has been validated in accordance with health authority requirements pertaining to computerized systems used in clinical research. An acceptable computerized data collection system allows preservation of the original entry of data. If original data are modified, the system should maintain a viewable audit trail that shows the original data as well as the reason for the change, name of the person making the change, and date of the change. 7.6 Retention of Records Records and documents pertaining to the conduct of this study, includi ng but not limited to eCRFs, paper PRO data, Informed Consent Forms, must be retained by the Principal Investigator for at least 15 years after completion or discontinuation of the study or for the length of time required by relevant national or local health authorities, whichever is longer. After that period of time, the documents may be destroyed, subject to local regulations."
45,page_45,"F. Hoffmann -La Roche Ltd Protocol MA39297, Version 1, 2 6 April 2017 45 No records may be disposed of without the written approval of the Sponsor. Writt en notification should be provided to the Sponsor prior to transferring any records to another party or moving them to another location. 8 ETHICAL CONSIDERATIO NS 8.1 Compliance with Laws and Regulations This study will be conducted in full conformance with the I CH E6 guideline for Good Clinical Practice and the principles of the Declaration of Helsinki, or the laws and regulations of the country in which the research is conducted, whichever affords the greater protection to the individual. The study will comply with the requirements of the ICH E2A guideline (Clinical Safety Data Management: Definitions and Standards for Expedited R eporting). 8.2 Informed Consent The Sponsor’s sample Informed Consent Form will be provided to each site in a certified translation of the local language. The Sponsor or its designee must review and approve any proposed deviations from the Sponsor's sample Informed Consent Forms or any alternate consent forms proposed by the site (collectively, the ""Consent Forms"") before IRB/EC submission. The final IRB/EC- approved Consent Forms must be provided to the Sponsor for health authority submission purposes according to local requirements. If applicable, the Informed Consent Form will contain separate sections for any optional procedures. The Invest igator or authorized designee will explain to each patient the objectives, methods, and potential risks associated with each optional procedure. Patients will be told that they are free to refuse to participate and may withdraw their consent at any time for any reason. A separate, specific signature will be required to document a patient's agreement to participate in optional procedures. Patients who decline to participate will not provide a separate signature. The Consent Forms must be signed and dated by the patient or the patient’s legally authorized representative before his or her participation in the study. The case history or clinical records for each patient shall document the informed consent process and that written informed consent was obtained prior to participation in the study. The Consent Forms should be revised whenever there are changes to study procedures or when new information becomes available that may affect the willingness of the patient to participate. The final revised IRB/EC -approved Consent Forms must be provided to the Sponsor for health authority submission purposes."
46,page_46,"F. Hoffmann -La Roche Ltd Protocol MA39297, Version 1, 2 6 April 2017 46 Patients must be re -consented to the most current version of the Consent Forms (or to a significant new information/findings addendum in accordance with applicable laws and IRB/EC policy) during their participation in the study. For any updated or revised Consent Forms, the case history or clinical records for each patient shall document the informed consent process and that written informed consent was obtained using t he updated/revised Consent Forms for continued participation in the study. A copy of each signed Consent Form must be provided to the patient or the patient’s legally authorized representative. All signed and dated Consent Forms must remain in each patient’s study file or in the site file and must be available for verification by study monitors at any time. 8.3 Institutional Review Board or Ethics Committee This protocol, the Informed Consent Forms, any information to be given to the patient, and relevant supporting information must be submitted to the IRB/EC by the Principal Investigator and reviewed and approved by the IRB/EC before the study is initiated. In addition, any patient recruitment materials must be approved by the IRB/EC. The Principal Investigator is responsible for providing written summaries of the status of the study to the IRB/EC annually or more frequently in accordance with the requirements, policies, and procedures established by the IRB/EC. Investigators are also responsible for promptly informing the IRB/EC of any protocol amendments (see Section 9.6). 8.4 Confidentiality The Sponsor maintains confidentiality standards by coding each patient enrolled in the study through assignment of a unique patient identification number. This means that patient names are not included in data sets that are transmitted to any Sponsor location. Patient medical information obtained by this study is confidential and may be disclosed to third parties only as permitted by the Informed Consent Form (or separate authorization for use and disclosure of personal health information) signed by the patient, unless permitted or required by law. Medical information may be given to a patient’s personal physician or other appropriate medical personnel responsible for the patient’s welfare, for treatment purposes. Given the complexity and exploratory nature of exploratory biomarker analyses, data derived from these analyses will generally not be provided to study Investigators or patients unless required by law. The aggregate results of any conducted research will be"
47,page_47,"F. Hoffmann -La Roche Ltd Protocol MA39297, Version 1, 2 6 April 2017 47 available in accordance with the effective Roche policy on study data publication (see Section 9.5). Data generated by this study must be available for inspection upon request by representatives of national and local health authorities, Sponsor monitors, representatives, and collaborators, and the IRB/EC for each study site, as appropriate. 9 STUDY DOCUMENTATION, MONITORING, AND ADMINISTRATION 9.1 Study Documentation The Investigator must maintain adequate and accurate records to enable the conduct of the study to be fully documented, including, but not limited to, the protocol, protocol amendments, Informed Consent Forms, and documentation of IRB/EC and governmental approval. In addition, at the end of the study, the Investigator will receive the patient data, including an audit trail containing a complete record of all changes to data. 9.2 Protocol Deviations The Investigator should document and explain any protocol deviations. The Investigator should promptly report any deviations that might have an impact on patient safety and data integrity to the Sponsor and to the IRB/EC in accordance with established IRB/EC policies and procedures. The Sponsor will review all protocol deviations and assess whether any represent a serious breach of Good Clinical Practice guidelines and require reporting to health authorities. As per the Sponsor's standard operating procedures, prospective requests to deviate from the protocol, including requests to waive protocol eligibility criteria, are not allowed. 9.3 Site Inspections Site visits may be conducted by the Sponsor or an authorized representative for inspection of study data, patients' medical records, and eCRFs. The Investigator will permit national and local health authorities; Sponsor monitors, representatives, and collaborators; and the IRBs/ECs to inspect facilities and records relevant to this study. 9.4 Administrative Structure This trial will be sponsored and managed by F. Hoffmann- La Roche Ltd. The Sponsor will provide clinical operations management, data management, and medical monitoring. Approximately 50 sites globally will part icipate to enroll approximately 180 patients. Central facilities will be used for biomarker analyses of baseline samples as specified in Section 4.5."
48,page_48,"F. Hoffmann -La Roche Ltd Protocol MA39297, Version 1, 2 6 April 2017 48 The study will be conducted under the leadership of a Steering Committee. The Steering Committee is composed of experts i n the ILD field and members representing the Sponsor. The Steering Committee, together with the Sponsor, developed the study protocol and has overall responsibility for the study conduct and publication. A separate charter describing roles and responsibilities of the members of the committee will be maintained by the Sponsor. 9.5 Publication of Data and Protection of Trade Secrets Regardless of the outcome of a study, the Sponsor is dedicated to openly providing information on the study to healthcare professionals and to the public, both at scientific congresses and in peer -reviewed journals. The Sponsor will comply with all requirements for publication of study results. For more information, refer to the Roche Global Policy on Sharing of Clinical Trials Data at the following Web site: www.roche.com/roche global policy on sharing of clinical study information.pdf The results of this study may be published or pre sented at scientific congresses. The Investigator must agree to submit all manuscripts or abstracts to the Sponsor prior to submission for publication or presentation. This allows the Sponsor to protect proprietary information and to provide comments based on information from other studies that may not yet be available to the Investigator. In accordance with standard editorial and ethical practice, the Sponsor will generally support publication of multicenter trials only in their entirety and not as individual center data. In this case, a coordinating Investigator will be designated by mutual agreement. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements. Any formal publication of the study in which contribution of Sponsor personnel exceeded that of conventional monitoring will be considered as a joint publication by the Investigator and the appropriate Sponsor personnel. Any inventions and resulting patents, improvement s, and/or know -how originating from the use of data from this study will become and remain the exclusive and unburdened property of the Sponsor, except where agreed otherwise. 9.6 Protocol Amendments Any protocol amendments will be prepared by the Sponsor. Protocol amendments will be submitted to the IRB/EC and to regulatory authorities in accordance with local regulatory requirements."
49,page_49,
50,page_50,
51,page_51,
52,page_52,
53,page_53,
54,page_54,"F. Hoffmann -La Roche Ltd Protocol MA39297, Version 1, 2 6 April 2017 54 Appendix 1 Schedule of Activities Enrollment (Suspicion of IPF/ILD) [Baseline visit] Pre-diagnosis Assessment period (max 12 months) a [Visit 1] Day of initial Diagnosis [Visit 2] Post -diagnosis Assessment period (max. 6 months) a [Visit 3] End of study / Early termination b [End of Study visit] Informed consent c x Review of inclusion/exclusion criteria x Demographic data x General medical history and baseline conditions x Physical examination: Vital signs and weight x x x x x Height and body mass index (BMI) x Disease- relevant data, as available d x x x x x Home -based assessments: Daily spirometry e x x x x x Daily physical functional capacity assessments f x x x x x PRO g x x x x x Site assessments: FVC x x x x x 6MWT h x x x x x Serum sample for biomarker assessment (optional) i x Whole blood sample for biomarker assessment (optional) i x Concomitant medications j x x x x x"
55,page_55,"F. H off m a n n -L a R o c h e Lt d Pr ot o c ol M A 3 9 2 9 7, V er si o n 1, 2 6 A pril 2 0 1 7 5 5 E nr oll m e nt ( S u s pi ci o n of I P F/I L D) [B a s eli n e vi sit ] Pr e -di a g n o si s A s s e s s m e nt p eri o d ( m a x 1 2 m o nt h s) a [ Vi sit 1] D a y of i niti al Di a g n o si s [ Vi sit 2] P o st -di a g n o si s A s s e s s m e nt p eri o d ( m a x. 6 m o nt h s) a [ Vi sit 3] E n d of st u d y / E arl y t er mi n ati o n b [ E n d of St u d y vi sit] I n v e sti g at or / P ati e nt s ur v e y x N o n -el e cti v e h o s pit ali z ati o n s, a c ut e e x a c er b ati o n s, d e at h s, e v e nt s r el at e d t o st u d y -a s s e s s m e nt s x x x x 6 M W T = 6 -mi n ut e w al k t e st; E Q -5 D = E ur o Q o L Fi v e -Di m e n si o n 5- l e v el v er si o n ; F A S = F ati g u e A s s e s s m e nt S c al e; F V C =f or c e d vit al c a p a cit y; I L D =i nt er stiti al l u n g di s e a s e; I P F =i di o p at hi c p ul m o n ar y fi br o si s ; K- BI L D = Ki n g’ s Bri ef I nt er stiti al L u n g Di s e a s e; m M R C = m o difi e d M e di c al R e s e ar c h C o u n cil . P R O = p ati e nt -r e p ort e d o ut c o m e; V A S = Vi s u al A n al o g u e S c al e . a T h e l e n gt h of t hi s p eri o d m a y v ar y o n a n i n di vi d u al b a si s. D uri n g t h e s e a s s e s s m e nt p eri o d s, l o c al cli ni c al pr a cti c e s h o ul d b e f oll o w e d; h o w e v er, at l e a st 1 sit e vi sit h a s t o b e p erf or m e d. b E n d of st u d y f or a n i n di vi d u al p ati e nt: • S h o ul d n o di a g n o si s b e m a d e 1 2 m o nt h s aft er i n cl u si o n i nt o t h e st u d y, t h e p ati e nt will l e a v e t h e st u d y. • P ati e nt s di a g n o s e d wit h a n o n -I L D c o n diti o n will l e a v e t h e st u d y o n t h e d at e of di a g n o si s. • P ati e nt s di a g n o s e d wit h I P F or I L D will r e m ai n a n d b e f oll o w e d i n t h e st u d y u p t o t h e st art of dr u g tr e at m e nt ( wit hi n si x m o nt h s) or a m a xi m u m of si x m o nt h s if n o dr u g tr e at m e nt i s pr e s cri b e d c I nf or m e d c o n s e nt m u st b e d o c u m e nt e d b ef or e a n y st u d y -s p e cifi c pr o c e d ur e s ar e p erf or m e d. d D at a t o b e c oll e ct e d i n cl u d e, b ut ar e n ot li mit e d t o, p ul m o n ar y f u n cti o n t e st s ( e. g., F E V 1, D L C O ), b r o n c h o al v e ol ar l a v a g e , a n d l u n g bi o p s y r e s ult s ( a s a v ail a bl e). e D ail y s pir o m etr y will b e c o n d u ct e d b y t h e p ati e nt at h o m e u si n g t h e st u d y kit pr o vi d e d. S pir o m etr y a s s e s s m e nt s ( F V C) will b e c o n d u ct e d at a p pr o xi m at el y t h e s a m e ti m e e a c h d a y wit h t h e p ati e nt i n a s e at e d p o siti o n. f D ail y p h y si c al f u n cti o n al c a p a cit y a s s e s s m e nt s ( e. g., st e p s p er d a y, c al ori e e x p e n dit ur e) will b e m e a s ur e d o n a n o n g oi n g b a si s u si n g t h e a c c el er o m etr y d e vi c e pr o vi d e d. g P ati e nt s will c o m pl et e s p e cifi c q u e sti o n n air e s ( K -BI L D, m M R C, E Q -5 D -5 L, a n d F A S) a n d vi s u al a n al o g u e s c al e s ( c o u g h, ur g e t o c o u g h, a n d f ati g u e) u p o n r e q u e st fr o m t h e I n v e sti g at or. h T h e 6 M W T will b e p erf or m e d o nl y at sit e s w h er e a f or m ali z e d pr o c e s s i s a v ail a bl e a n d t h e t e st c a n b e p erf or m e d u n d er s af e c o n diti o n s i Pr o vi di n g a s er u m s a m pl e a n d a b l o o d s a m pl e f or bi o m ar k er a s s e s s m e nt i s o pti o n al f or p ati e nt s . S a m pli n g will o nl y b e c o n d u ct e d at sit e s wit h a p pr o pri at e i nfr a str u ct ur e f or bl o o d pr o c e s si n g. j I n cl u d e s a n y m e di c ati o n ( e. g., pr e s cri pti o n dr u g s, o v er -t h e -c o u nt er dr u g s, v a c ci n e s, h er b al or h o m e o p at hi c r e m e di e s, n utriti o n al s u p pl e m e nt s) u s e d b y a p ati e nt fr o m i n cl u si o n u ntil t h e e n d of t h e st u d y."
56,page_56,"F. Hoffmann -La Roche Ltd Protocol MA39297, Version 1, 2 6 April 2017 56 Appendix 2 Hand-Held Spirome try: Example of Disease Behavior in an Individual Patient Figure 4 shows the results of daily FVC measurements in a patient suffering a sudden and rapid decrease in FVC (Russell et al. 2016). This decrease may not have been detected the patient only been assessed using longer intervals between measurements. Figure 4 Daily FVC Measurements over Time"
